Predictive Oncology (POAI) S-4/A 24 Jan 19 2018 Q3 Registration of securities issued in business combination transactions (amended) Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2018shares
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	1,446,159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)	13,398,339
Document Type	S-4/A
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	true
Amendment Description	This Registration Statement shall hereafter become effective in accordance with the provisions of Section 8(a) of the Securities Act of 1933.
Entity Ex Transition Period	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current Assets:
Cash & cash equivalents	$ 209,891	$ 766,189
Certificates of deposit		244,971
Accounts Receivable	238,598	137,499
Loan Receivable – Bridge Loan	1,815,000
Notes Receivable	163,468	667,512
Inventories	278,155	265,045
Prepaid Expense and other assets	404,428	289,966
Total Current Assets	3,109,540	2,371,182
Notes Receivable	1,134,774	1,070,000
Fixed Assets, net	198,258	87,716
Intangibles, net	973,127	95,356
Total Assets	5,415,699	3,624,254
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	409,099	140,462
Note Payable – Bridge Loan Net of Discount of $1,293,047	1,004,680
Accrued Expenses	315,039	785,215
Derivative Liability	645,008
Deferred Revenue	15,306	6,663
Total Liabilities	2,389,132	932,340
Commitments and Contingencies
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 6,943,283 and 4,564,428 outstanding	133,983	69,432
Additional paid-in capital	(64,297,137)	(57,380,256)
Accumulated deficit	61,405,345	54,765,045
Total Stockholders' Equity	3,026,567	2,691,914
Total Liabilities and Stockholders' Equity	5,415,699	3,624,254
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock		$ 6,479

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Discount of note payable	$ 1,293,047	$ 0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	13,398,339	6,943,283
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Revenue			$ 1,100,108	$ 434,523	$ 654,836	$ 456,495
Cost of goods sold			309,320	87,709	148,045	181,620
Gross margin			790,788	346,814	506,791	274,875
General and administrative expense			2,708,274	3,968,493	6,041,485	5,174,799
Operations expense			1,390,434	575,467	1,207,724	1,158,117
Sales and marketing expense			1,726,087	680,396	1,004,175	467,970
Total Expense			5,824,795	5,224,356	8,253,384	6,800,889
Loss on equity method investment			(1,606,294)
Net loss available to common shareholders	$ (2,506,869)	$ (992,095)	(6,640,301)	(4,877,542)	(7,746,593)	(6,526,014)
Comprehensive loss	$ (2,506,869)	$ (992,095)	$ (6,640,301)	$ (4,877,542)	$ (7,746,593)	$ (6,524,513)
Loss per common share - basic and diluted (in dollars per share)	$ (0.19)	$ (0.16)	$ (0.55)	$ (0.78)	$ (1.22)	$ (2.31)
Weighted average shares used in computation - basic and diluted (in shares)			12,178,285	6,283,567	6,362,989	2,823,345

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Over-Allotment Option [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Over-Allotment Option [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Over-Allotment Option [Member]Preferred Stock [Member]	Over-Allotment Option [Member]Common Stock [Member]	Over-Allotment Option [Member]Additional Paid-in Capital [Member]	Over-Allotment Option [Member]Retained Earnings [Member]	Over-Allotment Option [Member]AOCI Attributable to Parent [Member]	Over-Allotment Option [Member]	Helomics Holding Corp. [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Helomics Holding Corp. [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Helomics Holding Corp. [Member]Preferred Stock [Member]	Helomics Holding Corp. [Member]Common Stock [Member]	Helomics Holding Corp. [Member]Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member]Retained Earnings [Member]	Helomics Holding Corp. [Member]AOCI Attributable to Parent [Member]	Helomics Holding Corp. [Member]	Consulting Agreement One [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Consulting Agreement One [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Consulting Agreement One [Member]Preferred Stock [Member]	Consulting Agreement One [Member]Common Stock [Member]	Consulting Agreement One [Member]Additional Paid-in Capital [Member]	Consulting Agreement One [Member]Retained Earnings [Member]	Consulting Agreement One [Member]AOCI Attributable to Parent [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Consulting Agreement Two [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Consulting Agreement Two [Member]Preferred Stock [Member]	Consulting Agreement Two [Member]Common Stock [Member]	Consulting Agreement Two [Member]Additional Paid-in Capital [Member]	Consulting Agreement Two [Member]Retained Earnings [Member]	Consulting Agreement Two [Member]AOCI Attributable to Parent [Member]	Consulting Agreement Two [Member]	Consultant Contract One [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Consultant Contract One [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Consultant Contract One [Member]Preferred Stock [Member]	Consultant Contract One [Member]Common Stock [Member]	Consultant Contract One [Member]Additional Paid-in Capital [Member]	Consultant Contract One [Member]Retained Earnings [Member]	Consultant Contract One [Member]AOCI Attributable to Parent [Member]	Consultant Contract One [Member]	Consultant Contract Two [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Consultant Contract Two [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Consultant Contract Two [Member]Preferred Stock [Member]	Consultant Contract Two [Member]Common Stock [Member]	Consultant Contract Two [Member]Additional Paid-in Capital [Member]	Consultant Contract Two [Member]Retained Earnings [Member]	Consultant Contract Two [Member]AOCI Attributable to Parent [Member]	Consultant Contract Two [Member]	Contract with TumorGenesis [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Contract with TumorGenesis [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Contract with TumorGenesis [Member]Preferred Stock [Member]	Contract with TumorGenesis [Member]Common Stock [Member]	Contract with TumorGenesis [Member]Additional Paid-in Capital [Member]	Contract with TumorGenesis [Member]Retained Earnings [Member]	Contract with TumorGenesis [Member]AOCI Attributable to Parent [Member]	Contract with TumorGenesis [Member]	Series E Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]	Series E Warrants [Member]Common Stock [Member]	Series E Warrants [Member]Additional Paid-in Capital [Member]	Series E Warrants [Member]Retained Earnings [Member]	Series E Warrants [Member]AOCI Attributable to Parent [Member]	Series E Warrants [Member]	Re-priced Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Re-priced Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Re-priced Warrants [Member]Preferred Stock [Member]	Re-priced Warrants [Member]Common Stock [Member]	Re-priced Warrants [Member]Additional Paid-in Capital [Member]	Re-priced Warrants [Member]Retained Earnings [Member]	Re-priced Warrants [Member]AOCI Attributable to Parent [Member]	Re-priced Warrants [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2015																																																																											$ 18,950	$ 2,080	$ 44,584,118	$ (40,492,437)		$ 4,112,711
Balance (in shares) at Dec. 31, 2015																																																																												208,259
Vesting Expense																																																																													165,271			165,271
Unrealized (loss) from marketable securities																																																																															$ 1,501	1,501
Net loss																																																																														(6,526,014)		(6,526,014)
Balance at Dec. 31, 2016																																																																											792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																																																																										79,246		4,564,428
Shares issued pursuant to the public offering				$ 1,750	$ 392,000			$ 393,750																																																																				$ 17,500	3,403,688			3,421,188
Shares issued pursuant to the public offering (in shares)				175,000																																																																								1,750,000
Vesting Expense																																																																													2,142,189			2,142,189
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																																																												$ (4,000)				(4,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																																																												(400,000)
Shares issued for services																				$ 1,000	$ 219,000			$ 220,000				$ 433	$ 63,699			$ 64,132
Shares issued for services (in shares)																				100,000								43,333
Unrealized (loss) from marketable securities																																																																															(1,501)	(1,501)
Net loss																																																																														(4,877,542)		(4,877,542)
Balance at Sep. 30, 2017																																																																											792	$ 62,327	54,114,771	(51,895,993)		2,281,897
Balance (in shares) at Sep. 30, 2017																																																																										79,246		6,232,761
Balance at Dec. 31, 2016																																																																											792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																																																																										79,246		4,564,428
Shares issued pursuant to the public offering				$ 1,750	392,000			393,750																																																																				$ 17,500	3,403,688			3,421,188
Shares issued pursuant to the public offering (in shares)				175,000																																																																								1,750,000
Vesting Expense																																																																													4,042,256			4,042,256
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																																																												$ (4,000)				(4,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																																																												(400,000)
Unrealized (loss) from marketable securities																																																																														(1)	(1,501)
Net loss																																																																														(7,746,593)		(7,746,593)
Balance at Dec. 31, 2017																																																																											7,271	$ 69,432	57,380,256	(54,765,045)		2,691,914
Balance (in shares) at Dec. 31, 2017																																																																									647,819	79,246		6,943,283
Preferred conversion to common shares pursuant to private placement agreement																																																																											(5,659)	$ 6,604	85,236			86,182
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																																																												660,522
Shares issued pursuant to the public offering				$ 2,153	$ 202,268	$ 1		$ 204,422																																																																				$ 29,000	2,726,087			2,755,087
Shares issued pursuant to the public offering (in shares)				215,247																																																																								2,900,000
Vesting Expense																																																																													800,322			800,322
Shares issued for services																																				$ 1,500	$ 175,500			$ 177,000				$ 1,000	$ 117,000			$ 118,000
Shares issued for services (in shares)																																				150,000								100,000
Net loss																																																																														(6,640,301)		(6,640,301)
Balance at Sep. 30, 2018																																																																											792	$ 133,983	64,297,137	(61,405,345)		3,026,567
Balance (in shares) at Sep. 30, 2018																																																																										79,246		13,398,339
Preferred conversion to common shares pursuant to private placement agreement																																																																											(6,479)	$ 5,897	582			0
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																																																									(647,819)			589,747
Investment pursuant to Helomics 20% acquisition												$ 11,000	$ 1,031,250			$ 1,042,250
Investment pursuant to Helomics 20% acquisition (in shares)												1,100,000
Warrant exercises																																																												$ 1,454	$ 143,942			$ 145,396				$ 5,046	$ 499,619			$ 504,665
Warrant exercises (in shares)																																																												145,396								504,666
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share																																																				$ 7,500	$ 870,000			$ 877,500
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share (in shares)																																																				750,000
Stock issuable for bridge loan																																																																													206,605			206,605
Warrants issued per bridge loan																																																																													$ 143,707			$ 143,707

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals)	Sep. 30, 2018$ / shares
Series E Warrants [Member] | Common Stock [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Common Stock [Member] | Over-Allotment Option [Member]
Price of shares issued (in dollars per share)	0.9497
Common Stock [Member] | Consultant Contract One [Member]
Price of shares issued (in dollars per share)	1.18
Common Stock [Member] | Consultant Contract Two [Member]
Price of shares issued (in dollars per share)	1.18
Common Stock [Member] | Contract with TumorGenesis [Member]
Price of shares issued (in dollars per share)	$ 1.17

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flow from operating activities:
Net loss	$ (6,640,301)	$ (4,877,542)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment	1,606,294
Depreciation and amortization	105,569	53,831
Vested stock options and warrants	800,322	2,142,189
Equity instruments issued for management and consulting	295,000	280,133
Gain (loss) from sale of marketable securities		(1,837)
Changes in assets and liabilities:
Accounts receivable	(101,099)	(52,789)
Inventories	(13,110)	33,319
Prepaid expense and other assets	70,536	(48,188)
Accounts payable	268,637	(145,470)
Accrued expenses	(470,176)	(523,142)
Deferred revenue	8,643	2,187
Net cash used in operating activities	(4,069,685)	(3,137,309)
Cash flow from investing activities:
Proceeds from sale of marketable securities		284,665
Purchase of certificates of deposit		(2,594,728)
Redemption of certificates of deposit	244,971	1,470,000
Advance on notes receivable	(124,774)	(785,000)
Purchase of fixed assets	(169,983)	(43,251)
Purchase of intangibles	(46,398)	(7,701)
Net cash used in investing activities:	(96,184)	(1,676,015)
Cash flow from financing activities:
Proceeds from exercise of warrants into common stock	650,062
Issuance of common stock	2,959,509	3,814,938
Net cash provided by financing activities	3,609,571	3,814,938
Net increase (decrease) in cash and cash equivalents	(556,298)	(998,386)
Cash at beginning of period	766,189	1,764,090
Cash at end of period	209,891	765,704
Non-cash transactions:
Shares issued into escrow for TumorGenesis	877,500
Bridge loan receivable	1,815,000
Conversion of Preferred Stock to Common Stock	6,479
Equity method investment - Helomics	$ 1,542,250

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash & cash equivalents	$ 209,891	$ 766,189	$ 1,764,090
Certificates of deposit		244,971	100,000
Marketable securities			284,329
Accounts Receivable	238,598	137,499	38,919
Notes Receivable	163,468	667,512
Inventories	278,155	265,045	272,208
Prepaid Expense and other assets	404,428	289,966	148,637
Total Current Assets	3,109,540	2,371,182	2,608,183
Notes Receivable	1,134,774	1,070,000
Fixed Assets, net	198,258	87,716	101,496
Intangibles, net	973,127	95,356	97,867
Total Assets	5,415,699	3,624,254	2,807,546
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	409,099	140,462	220,112
Accrued Expenses	315,039	785,215	1,346,105
Deferred Revenue	15,306	6,663	7,998
Total Current Liabilities		932,340	1,574,215
Accrued Expenses			309,649
Total Liabilities	2,389,132	932,340	1,883,864
Commitments and Contingencies
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 6,943,283 and 4,564,428 outstanding	133,983	69,432	45,644
Additional paid-in capital	(64,297,137)	(57,380,256)	(47,894,196)
Accumulated deficit	61,405,345	54,765,045	47,018,451
Accumulated Other Comprehensive Income			1,501
Total Stockholders' Equity	3,026,567	2,691,914	923,682
Total Liabilities and Stockholders' Equity	5,415,699	3,624,254	2,807,546
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	792	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock		$ 6,479

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	13,398,339	6,943,283	4,564,428
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819	0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 654,836	$ 456,495
Cost of goods sold	148,045	181,620
Gross margin	506,791	274,875
General and administrative expense	6,041,485	5,174,799
Operations expense	1,207,724	1,158,117
Sales and marketing expense	1,004,175	467,970
Interest expense		3
Total Expense	8,253,384	6,800,889
Net loss available to common shareholders	(7,746,593)	(6,526,014)
Other comprehensive income
Unrealized (loss) from marketable securities		1,501
Comprehensive loss	$ (7,746,593)	$ (6,524,513)
Loss per common share - basic and diluted (in dollars per share)	$ (1.22)	$ (2.31)
Weighted average shares used in computation - basic and diluted (in shares)	6,362,989	2,823,345

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Series A Warrants [Member]Common Stock [Member]	Series A Warrants [Member]Additional Paid-in Capital [Member]	Series A Warrants [Member]	Series B Warrants [Member]Common Stock [Member]	Series B Warrants [Member]Additional Paid-in Capital [Member]	Series B Warrants [Member]	Investment Banker [Member]Common Stock [Member]	Investment Banker [Member]Additional Paid-in Capital [Member]	Investment Banker [Member]	Investor Relations Consultant [Member]Common Stock [Member]	Investor Relations Consultant [Member]Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	GLG Pharma, LLC. [Member]Common Stock [Member]	GLG Pharma, LLC. [Member]	Former CEO [Member]Common Stock [Member]	Former CEO [Member]Additional Paid-in Capital [Member]	Former CEO [Member]	The 2016 Registered Direct Offering [Member]Common Stock [Member]	The 2016 Registered Direct Offering [Member]Additional Paid-in Capital [Member]	The 2016 Registered Direct Offering [Member]	Over-Allotment Option [Member]Preferred Stock [Member]	Over-Allotment Option [Member]Common Stock [Member]	Over-Allotment Option [Member]Additional Paid-in Capital [Member]	Over-Allotment Option [Member]Retained Earnings [Member]	Over-Allotment Option [Member]AOCI Attributable to Parent [Member]	Over-Allotment Option [Member]	Consulting Agreement One [Member]Common Stock [Member]	Consulting Agreement One [Member]Additional Paid-in Capital [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member]Common Stock [Member]	Consulting Agreement Two [Member]Additional Paid-in Capital [Member]	Consulting Agreement Two [Member]	Investor Relations Consultant [Member]Common Stock [Member]	Investor Relations Consultant [Member]Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	Private Placement [Member]Preferred Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2015																																							$ 18,950	$ 2,080	$ 44,584,118	$ (40,492,437)		$ 4,112,711
Balance (in shares) at Dec. 31, 2015																																								208,259
Shares issued for two options exercised at $65.75 per share (in shares)																																								1,312
Shares issued for two options exercised at $65.75 per share																																								$ 13	86,240			86,253
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering																																							(18,158)	$ 664	17,494			0
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering (in shares)																																								66,396
Warrant exercises (in shares)	2,318,663			628,237
Warrant exercises	$ 23,187	$ 556,479	$ 579,666	$ 6,282	$ 150,777	$ 157,059
Shares issued for services (in shares)							135,995
Shares issued for services							$ 1,360	$ 508,620	$ 509,980
Shares issued pursuant to the public offering (in shares)										26,000			400,000		20,000			756,999
Shares issued pursuant to the public offering										$ 260	$ 116,740	$ 117,000	$ 4,000	$ 4,000	$ 200	$ 90,151	$ 90,351	$ 7,570	$ 1,618,335	$ 1,625,905
Vesting Expense																																									165,271			165,271
Unrealized (loss) from marketable securities																																											$ 1,501	1,501
Corrections due to rounding for reverse split and DTCC increase (in shares)																																								2,567
Corrections due to rounding for reverse split and DTCC increase																																								$ 28	(29)			(1)
Net loss																																										(6,526,014)		(6,526,014)
Balance at Dec. 31, 2016																																							792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																																								4,564,428
Shares issued for services (in shares)
Shares issued pursuant to the public offering (in shares)																						175,000																		1,750,000
Shares issued pursuant to the public offering																						$ 1,750	$ 392,000			$ 393,750														$ 17,500	3,403,688			3,421,188
Vesting Expense																																									2,142,189			2,142,189
Unrealized (loss) from marketable securities																																											(1,501)	(1,501)
Net loss																																										(4,877,542)		(4,877,542)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																								(400,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																								$ (4,000)				(4,000)
Balance at Sep. 30, 2017																																							792	$ 62,327	54,114,771	(51,895,993)		2,281,897
Balance (in shares) at Sep. 30, 2017																																								6,232,761
Balance at Dec. 31, 2016																																							792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																																								4,564,428
Shares issued for services (in shares)																											100,000			43,333			50,000
Shares issued for services																											$ 1,000	$ 219,000	$ 220,000	$ 433	$ 63,699	$ 64,132	$ 500	$ 78,500	$ 79,000
Shares issued pursuant to the public offering (in shares)																						175,000																		1,750,000
Shares issued pursuant to the public offering																						$ 1,750	392,000			393,750										$ 12,138	$ 1,201,681	$ 1,213,819		$ 17,500	3,403,688			3,421,188
Vesting Expense																																									4,042,256			4,042,256
Unrealized (loss) from marketable securities																																										(1)	(1,501)
Net loss																																										(7,746,593)		(7,746,593)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																								(400,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																								$ (4,000)				(4,000)
Preferred conversion to common shares pursuant to private placement agreement																																							(5,659)	$ 6,604	85,236			86,182
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																								660,522
Balance at Dec. 31, 2017																																							7,271	$ 69,432	57,380,256	(54,765,045)		2,691,914
Balance (in shares) at Dec. 31, 2017																																								6,943,283
Shares issued pursuant to the public offering (in shares)																						215,247																		2,900,000
Shares issued pursuant to the public offering																						$ 2,153	$ 202,268	$ 1		$ 204,422														$ 29,000	2,726,087			2,755,087
Vesting Expense																																									800,322			800,322
Net loss																																										(6,640,301)		(6,640,301)
Preferred conversion to common shares pursuant to private placement agreement																																							(6,479)	$ 5,897	582			0
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																								589,747
Balance at Sep. 30, 2018																																							$ 792	$ 133,983	$ 64,297,137	$ (61,405,345)		$ 3,026,567
Balance (in shares) at Sep. 30, 2018																																								13,398,339

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parentheticals)	Dec. 31, 2017$ / shares
Investor Relations Consultant [Member]
Price of shares issued (in dollars per share)	$ 1.58

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flow from operating activities:
Net loss	$ (7,746,593)	$ (6,526,014)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	71,562	82,356
Vested stock options and warrants	4,042,256	165,271
Equity instruments issued for management and consulting	359,133	721,330
Issuance of common stock in cashless warrant exchange		736,725
(Gain) loss on Sales of Equipment		(2,387)
Gain (loss) from sale of marketable securities	(1,837)	(4,716)
Changes in assets and liabilities:
Accounts receivable	(98,580)	(636)
Inventories	7,163	(40,468)
Prepaid expense and other assets	(141,329)	122,943
Accounts payable	(79,650)	(430,301)
Accrued expenses	(870,540)	791,459
Deferred revenue	(1,335)	2,998
Net cash used in operating activities	(4,459,750)	(4,381,440)
Cash flow from investing activities:
Purchase of marketable securities		(850,000)
Proceeds from sale of marketable securities	284,665	571,887
Purchase of certificates of deposit	(3,084,971)	(1,100,000)
Redemption of certificates of deposit	2,940,000	1,000,000
Advance on notes receivable	(1,737,512)
Purchase of fixed assets	(45,093)	(32,760)
Purchase of intangibles	(10,179)	(11,987)
Net cash used in investing activities:	(1,653,090)	(422,860)
Cash flow from financing activities:
Net proceeds from issuance of preferred stock	1,300,001
Net proceeds from issuance of common stock	3,814,938	1,712,158
Net cash provided by financing activities	5,114,939	1,712,158
Net increase (decrease) in cash and cash equivalents	(997,901)	(3,092,142)
Cash at beginning of period	1,764,090	4,856,232
Cash at end of period	$ 766,189	$ 1,764,090

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of September 30, 2018, 13,398,339 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, 4. 149,000 first 2018, The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $61,405,345. not $209,891 September 30, 2018 one not $1,815,000, September 28, 2018. first October 2018 September 28, 2018 Since inception to September 30, 2018, $36,490,000 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 $36,490,000 $3,405,052 2018 $2,755,000 $650,062 $5,685,000 Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not Recent Accounting Developments In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018, no 3 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not January 1, 2018. June 30, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. 2016 02 not Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first September 30, 2018 December 31, 2017 Finished goods $ 61,587 $ 62,932 Raw materials 157,610 141,028 Work-In-Process 58,958 61,085 Total $ 278,155 $ 265,045 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: September 30, 2018 December 31, 2017 Computers and office equipment $ 204,904 $ 183,528 Leasehold improvements 140,114 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 77,496 43,368 Total 531,469 361,486 Less: Accumulated depreciation 333,211 273,770 Total Fixed Assets, Net $ 198,258 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $26,120 $59,442 three nine September 30, 2018 $14,561 $44,764 three nine September 30, 2017. Intangible Assets Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was $38,387 $46,127 three nine September 30, 2018 $3,276 $9,067 three nine September 30, 2017. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651 As of July 11, 2018, #EP2948200 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one no no Segments The Company operates in two three nine September 30, 2018 2017 $4,195 $288 three September 2018 2017, $10,061 $25,188 first nine 2018 2017, Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not	NOTE 1 Nature of Operations and Continuance of Operations The Company was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of December 31, 2017, 6,943,283 $.01 1 25 October 27, 2016. April 2009, 510 The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 not Since inception to December 31, 2017, $29,065,934 $2,055,000 $13,555,003 $1,739,770 $3,937,500 $358,312 $1,300,000 $5,685,000 Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Deferral of the Effective Date,” 2016 08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.” 2017 13. December 15, 2017, not two 606. January 1, 2018 January 1, 2018, not In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, first 2017. In July 2015, No. 2015 11 , Inventory (Topic 330 December 15, 2016, first 2017. In November 2015, 2015 17, “Income Taxes (Topic 740 December 15, 2016 first 2017. In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not December 15, 2017, not In February 2016, No. 2016 02, (Topic 842” 2016 02” December 15, 2018. In March 2016, No. 2016 09, “Compensation (Topic 718 “ASU2016 09” 2016 09 December 15, 2016. first 2017. In August 2016, No. 2016 15, Statement of Cash Flows (Topic 230 December 15, 2017, not 2016 15 On December 22, 2017, 2017 34% 21%. We reviewed all other significant newly issued accounting pronouncements and determined they are either not no Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may not may not not Accounting Policies and Estimate The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $37,060 2017, $71,212 2016. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $289,000 $406,000 2017 2016, Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Revenue Recognition and ASC 606 We recognize revenue when the following criteria are met: persuasive evidence of an arrangement exists – we receive both a signed purchase order and contract of terms and conditions confirming the sale from the customer; delivery has occurred – the goods are shipped from our warehouse and delivered and accepted by the customer; the selling price is fixed or determinable – confirmed on the customer purchase order and then invoiced immediately upon shipment of the goods; and collectability is reasonably assured – our customers are long standing hospitals, ambulatory surgical centers and others that pass credit checks. The terms of our agreements with our customers are specified in written agreements. These written agreements, the purchase order and the matching invoice, constitute the persuasive evidence of the arrangements with our customers that are a precondition to the recognition of revenue. We undertake an evaluation of the creditworthiness of both new and, on a periodic basis, existing customers. Based on these reviews we determine whether collection of our prospective revenue is probable. We have adopted the provisions of Accounting Standards Update, or “ASU” 2014 09, 606 606 January 1, 2018 While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will not Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Investment Securities Readily marketable investments in debt and equity services are classified as available-for-sale and are reported at fair value with unrealized gains losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method. Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $58,872 2017 $73,249 2016. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $12,689 2017 $9,107 2016. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes (“ASC 740” 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Patents and Intellectual Property On January 25th, 2014, No. PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651, Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $563,000 Product Warranty Costs In 2017 2016, $6,209 $34,665 Segments The Company operates in two 2017 2016 $26,662 2017. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not

Note 2 - Equity Method Investme

Note 2 - Equity Method Investment	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 2 The Company has an equity method investment in Helomics. The unaudited nine Helomics Holdings Corporation For the Nine Months Ended September 30, 2018 Revenue $ 623,662 Gross margin $ 441,370 Net loss from continuing operations $ (6,833,846 ) Net loss to investee $ (5,227,552 ) 1 1 80% January 11, 2018 – February 27, 2018, 75% nine Helomics’ first nine $31,000 third

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of September 30, 2018, December 31, 2017, $238,598 $137,499, three nine September 30, 2018, not The Company deferred revenues related primarily to maintenance plans of $15,306 $6,663 September 30, 2018 December 31, 2017, Practical Expedients The Company has elected the practical expedient not

Note 4 - Stockholders' Equity,

Note 4 - Stockholders' Equity, Stock Options and Warrants	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 4 2018 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% Share Exchange Agreement With Helomics On January 11, 2018, 2,500,000 1,100,000 March 2018 $500,000 5% 25% $500,000 1,100,000 12 $8,000,000. 20% may Merger Agreement with Helomics On June 28, 2018, October 26, 2018, 9. not 7.5 1.1 20% 860,000 18 $7.6 18.7 $1.00 5.0 $1.00 75% $7.6 0.6 $1.00 23.7 14.2 $1.00 995,000 $0.01 597,000 $0.01 Under the Merger Agreement, completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics. On July 10 11, 2018, 250,000 $0.01, $1.18 750,000 $0.01, $1.17 Increases in Authorized Shares At a special meeting of the stockholders on January 29, 2017, 8,000,000 24,000,000 At the annual meeting on December 28, 2017, 24,000,000 50,000,000 $0.01 January 2, 2018. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On January 15, 2018, 50,000 $0.01 $0.97 four third fourth On March 12, 2018, 111,112 $0.01 $1.35 four third fourth For grants of stock option and warrants in 2018 2.33% 3.05% 0% 59% 66% 5 10 $0.4816 $1.0044 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 836,950 1.12 2,028,776 1.08 Expired (153,048 ) 2.00 (10,706 ) 199.55 Exercised - - (650,062 ) 1.00 Outstanding at September 30, 2018 3,448,885 $ 1.78 3,319,265 $ 4.55 At September 30, 2018, 2,522,848 $1.93 9.01 2,247,489 nine September 2018 September 2017 $800,322 7,908 $930,349 21 The following summarizes the status of options and warrants outstanding at September 30, 2018: Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.55 $ 0.965 3,000 9.63 $ 0.97 191,753 9.27 $ 1.01 149,110 9.38 $ 1.06 23,585 10.00 $ 1.10 86,958 9.71 $ 1.13 195,931 9.80 $ 1.15 21,740 9.84 $ 1.16 66,451 9.84 $ 1.18 30,000 9.86 $ 1.20 41,668 9.84 $ 1.21 30,000 9.86 $ 1.35 111,112 9.45 $ 1.454 17,200 9.01 $ 1.47 2,347,308 8.73 $ 2.10 14,286 8.50 $ 2.25 293 7.90 $ 2.42 20,640 7.84 $ 2.80 57,145 8.26 $ 3.75 3,998 5.24 $ 4.125 3,636 8.01 $ 4.1975 7,147 7.97 $ 4.25 3,529 7.50 $ 5.125 3,902 7.94 $ 65.75 190 7.06 $ 73.50 1,157 7.26 $ 77.50 2,323 6.75 $ 80.25 187 7.01 $ 86.25 232 6.50 $ 131.25 81 3.94 $ 148.125 928 4.47 $ 150.00 1,760 3.88 $ 162.50 123 6.26 $ 206.25 121 6.01 $ 248.4375 121 4.79 $ 262.50 130 4.79 $ 281.25 529 4.30 $ 318.75 3 4.60 $ 346.875 72 5.50 $ 431.25 306 5.44 $ 506.25 188 5.25 $ 596.25 42 5.00 3,448,885 Warrants $ 1.00 1,063,935 4.60 $ 1.07 697,946 4.10 $ 1.155 1,071,776 5.00 $ 2.25 385,000 3.32 $ 123.75 94,084 1.92 $ 243.75 2,529 0.84 $ 309.375 2,850 0.86 $ 309.50 222 1.10 $ 506.25 59 0.38 $ 609.375 862 0.34 3,319,265 At the annual meeting on December 28, 2017, 2012 5,000,000, December 4, 2017, 2012 2016 July 28, 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of September 30, 2018 Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,503,152 1.01 - 2.10 2018 836,950 0.91 - 1.35 Total 3,448,885 $0.91 – $596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 252,333 1.00 2017 1,082,946 1.07 - 2.25 2018 1,883,380 1.00 - 1.155 Total 3,319,265 $0.00 – $609.38	NOTE 3 2015 On August 31, 2015 ( 1,666,667 $9.00 $8.28 $0.72 8.00% $13.8 45 250,000 not 1% $70,000. On August 31, 2015, 228,343 1,895,010 75,801 1,895,010 7,580,040 Each Unit consisted of one $0.01 one four February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Certificate of Designation for Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants August 31, 2020. one $123.75 Holders may Total Shares = (A x Where: ☐ Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. ☐ A is the total number of shares with respect to which the Series A Warrant is then being exercised. ☐ B is the Black Scholes Value (as defined below). ☐ C is the closing bid price of the Common Stock as of two no may $0.43 The Black Scholes Value (as defined above) as of September 30, 2016 $4.319, September 30, 2016, $4.125. .40 6,141,115 September 30, 2016, 2,318,663 35,084 August 31, 2015 two $0.43 $4.319 September 30, 2016), 564 The Series A Warrants will not 4.99% 13 1934, In addition to (but not three 1 2 Unit Purchase Option The Company, in connection with the Offering, entered into a Unit Purchase Option Agreement, dated as of August 31, 2015 ( 5% 83,333 125% $11.25 May 2016 135,995 Series B Preferred Stock Each share of Series B Preferred Stock is convertible into one six not 4.99% no No Unit Exchange On February 4, 2014, $2,055,000 20,550 $0.01, $100 February 4, 2014. August 31, 2015, 228,343 3,391 3 9 August 31, 2015, no Redemption of Convertible Notes In connection with the closing of the Offering, $933,074 40% $1,548,792. 4. $167,031 Registered Exchange Offer for Warrants On March 25, 2016, $0.01 3,157,186 March 31, 2016, 10.05 may one 10.2 one April 21, 2016. 1,770,556 18,059,671 March 31, 2016 July 6, 2016 1,251,510 20,122 2016 On November 29, 2016, $1,983,337. 756,999 $2.62 five 756,999 six $4.46 $1,739,770. 2017 On January 19, 2017 1,750,000 $2.25 one 0.2 one $2.25 $3,937,500. 175,000 35,000 $0.01 $358,312. 2017 On November 30, 2017, 1,213,819 $1.071 606,910 $1.26 five one six $1,300,000 1.167 1,250,269 142,466 $189,285. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company has adopted ASC 718 Compensation-Stock Compensation 718" 718 January 1, 2006 January 1, 2006. January 1, 2006, not ASC 718 Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On July 1, 2016, 40,000 $0.01 $3.75 six fifth sixth On October 4, 2016, 400,000 $0.01, For grants of stock options and warrants in 2016 1.46% 2.45% 0% 59% 66% 5 10 $1.6329 $3.7195 On April 19, 2017, 400,000 $0.01, For grants of stock options and warrants in 2017 1.92% 2.40% 0% 59% 66% 5 10 $0.6541 $1.5489 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 At December 31, 2017, 1,728,264 $2.29 9.45 1,253,311 2017 2016 $1,892,159 $165,271, $1,139,172 24 The following summarizes the status of options and warrants outstanding at December 31, 2017: Range of Exercise Prices Shares Weighted Options: $ 1.01 124,358 10.00 $ 1.454 17,200 9.75 $ 1.47 2,456,226 9.48 $ 2.10 14,286 9.25 $ 2.25 293 8.65 $ 2.42 24,768 8.38 $ 2.80 57,145 9.01 $ 3.75 44,000 8.50 $ 4.125 3,636 8.75 $ 4.1975 7,147 8.72 $ 4.25 3,529 8.25 $ 5.125 3,902 8.69 $ 65.75 190 7.40 $ 73.50 1,157 8.01 $ 77.50 2,323 7.50 $ 80.25 187 7.75 $ 86.25 232 7.25 $ 131.25 81 4.69 $ 148.125 928 5.21 $ 150.00 1,760 4.63 $ 162.50 123 7.01 $ 206.25 121 6.75 $ 248.4375 121 5.54 $ 262.50 130 5.54 $ 281.25 529 5.04 $ 318.75 3 5.35 $ 346.875 72 6.25 $ 431.25 306 6.19 $ 506.25 188 6.00 $ 596.25 42 5.75 Total 2,764,983 Warrants $ 1.07 697,946 4.85 $ 2.25 385,000 4.06 $ 4.46 756,999 3.92 $ 93.75 2,255 0.19 $ 123.75 94,084 2.67 $ 150.00 4,114 0.20 $ 225.00 107 0.07 $ 243.75 2,529 1.59 $ 281.25 3,107 0.14 $ 309.375 2,850 1.61 $ 309.50 222 1.85 $ 337.50 178 0.46 $ 371.25 944 0.41 $ 506.25 59 1.12 $ 609.375 862 1.09 Total 1,951,257 Stock options and warrants expire on various dates from January 2018 December 2027. At a special meeting of stockholders held on September 15, 2016, 100,000,000 200,000,000 September 16, 2016, October 26, 2016, one twenty-five 1:25 200,000,000 8,000,000 5:00 October 27, 2016, October 28, 2016. may January 29, 2017. 8,000,000 24,000,000 December 28, 2017, January 2, 2018, 24,000,000 50,000,000 $0.01 2012 5,000,000, December 4, 2017, 2012 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of December 31, 2017 Stock Options: Year Shares Price 2011 173 281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 835 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,423 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 Total 2,764,983 $ 1.01 – 596.25 Warrants: Year Shares Price 2013 10,705 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 Total 1,951,257 $ 0.00 – 609.38

Note 5 - Notes Receivable

Note 5 - Notes Receivable	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, 8% two February 28, 2020. July 2018. not August, September October. September 27 28, 2018 October 2018, not not In October 2017, $600,000 December 2017, $67,512 fifty 50% March 2018, $500,000 833,333 5% 25%. In September 2018, $60,000 $163,468, September 30, 2018. October 2018, $907,500 9.	NOTE 4– In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, eight 8% two February 28, 2020. The Company advanced $600,000 8% April 30, 2018. December 2017, $67,512.10 fifty 50% March 2018, $500,000 833,333 5% 25%. $167,512.10

Note 6 - Convertible Debt and D

Note 6 - Convertible Debt and Derivative Liability	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Convertible Debt and Derivative Liability [Text Block]	NOTE 6 Effective September 28, 2018 ( two $2,297,727 9 October 3, 2018, $1,815,000, $2,000,000 September 30, 2018 one second $500,000 $2,865,909.00. 650,000 1,071,776 $1.155 second 1,336,805 sixth fifth The notes accrue interest at a rate of 8% twelve twelve $1.00 70% 20 may 2,678,328 Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using 70% 20 The Company accounted for the warrants by deriving the Black-Scholes value ascertained with a discount rate of 2.94% five 59% .5361 $574,631. The value of the embedded derivative was based upon level 3 1.

Note 7 - Loss Per Share

Note 7 - Loss Per Share	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 7 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,506,869 ) $ (992,095 ) $ (6,640,301 ) $ (4,877,542 ) Comprehensive loss (2,506,869 ) (992,095 ) (6,640,301 ) (4,877,542 ) Denominator: Weighted average common shares outstanding-basic 13,252,605 6,232,761 12,178,285 6,283,567 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 13,252,605 6,262,761 12,178,285 6,283,567 Loss per common share-basic and diluted $ (0.19 ) $ (0.16 ) $ (0.55 ) $ (0.78 ) ( 1 September 30, 2018 September 30, 2017 6,768,151 3,866,849, September 30, 2018 5,047,700. September 30, 2018 79,246.	NOTE 5 The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended December 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (7,746,593 ) $ (6,526,014 ) Other comprehensive income: Unrealized gain (loss) from marketable securities - 1,501 Comprehensive (loss) (7,746,593 ) (6,524,513 ) Denominator: Weighted average common shares outstanding-basic 6,362,989 2,823,345 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,362,989 2,823,345 Loss per common share-basic and diluted $ (1.22 ) $ (2.31 ) ( 1 December 31, 2017 December 31, 2016 4,716,240 1,036,744, December 31, 2017 79,246 647,819

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 8 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may In April 2018, one six $12,000 240,000 2012 six October 2018. April 2018 not	NOTE 8 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. In September 20, 2016, 400,000 four 100,000 November 1, 2016, November 2, 2016, April 2017,

Note 9 - Subsequent Events

Note 9 - Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 9 Private Placement of Convertible Secured Notes Effective as of September 28, 2018 ( two $2,297,727.50 October 3, 2018, $1,815,000, $2,000,000 September 30, 2018 one second $500,000 $2,865,909.00. 650,000 1,071,776 $1.155 second 1,336,805 sixth fifth The notes accrue interest at a rate of 8% twelve twelve $1.00 70% 20 may 2,678,328 Amended and Restated Merger Agreement On October 26, 2018, June 28, 2018. not 4 3.5 7.5 4 1.1 20% not one 4.	NOTE 11 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% On January 11, 2018, 2,500,000 1,100,000 $500,000 5% 25% $500,000 12 $8,000,000. 20% may On February 22, 2018, $667,512.50. $500,000 833,333 2,500,000 10,000,000 3,333,333 25% 13,333,333 $167,512.50 On February 27, 2018, may 25% 48Hour

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies -2	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of September 30, 2018, 13,398,339 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, 4. 149,000 first 2018, The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $61,405,345. not $209,891 September 30, 2018 one not $1,815,000, September 28, 2018. first October 2018 September 28, 2018 Since inception to September 30, 2018, $36,490,000 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 $36,490,000 $3,405,052 2018 $2,755,000 $650,062 $5,685,000 Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not Recent Accounting Developments In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018, no 3 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not January 1, 2018. June 30, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. 2016 02 not Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first September 30, 2018 December 31, 2017 Finished goods $ 61,587 $ 62,932 Raw materials 157,610 141,028 Work-In-Process 58,958 61,085 Total $ 278,155 $ 265,045 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: September 30, 2018 December 31, 2017 Computers and office equipment $ 204,904 $ 183,528 Leasehold improvements 140,114 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 77,496 43,368 Total 531,469 361,486 Less: Accumulated depreciation 333,211 273,770 Total Fixed Assets, Net $ 198,258 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $26,120 $59,442 three nine September 30, 2018 $14,561 $44,764 three nine September 30, 2017. Intangible Assets Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was $38,387 $46,127 three nine September 30, 2018 $3,276 $9,067 three nine September 30, 2017. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651 As of July 11, 2018, #EP2948200 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one no no Segments The Company operates in two three nine September 30, 2018 2017 $4,195 $288 three September 2018 2017, $10,061 $25,188 first nine 2018 2017, Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not	NOTE 1 Nature of Operations and Continuance of Operations The Company was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of December 31, 2017, 6,943,283 $.01 1 25 October 27, 2016. April 2009, 510 The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 not Since inception to December 31, 2017, $29,065,934 $2,055,000 $13,555,003 $1,739,770 $3,937,500 $358,312 $1,300,000 $5,685,000 Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Deferral of the Effective Date,” 2016 08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.” 2017 13. December 15, 2017, not two 606. January 1, 2018 January 1, 2018, not In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, first 2017. In July 2015, No. 2015 11 , Inventory (Topic 330 December 15, 2016, first 2017. In November 2015, 2015 17, “Income Taxes (Topic 740 December 15, 2016 first 2017. In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not December 15, 2017, not In February 2016, No. 2016 02, (Topic 842” 2016 02” December 15, 2018. In March 2016, No. 2016 09, “Compensation (Topic 718 “ASU2016 09” 2016 09 December 15, 2016. first 2017. In August 2016, No. 2016 15, Statement of Cash Flows (Topic 230 December 15, 2017, not 2016 15 On December 22, 2017, 2017 34% 21%. We reviewed all other significant newly issued accounting pronouncements and determined they are either not no Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may not may not not Accounting Policies and Estimate The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $37,060 2017, $71,212 2016. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $289,000 $406,000 2017 2016, Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Revenue Recognition and ASC 606 We recognize revenue when the following criteria are met: persuasive evidence of an arrangement exists – we receive both a signed purchase order and contract of terms and conditions confirming the sale from the customer; delivery has occurred – the goods are shipped from our warehouse and delivered and accepted by the customer; the selling price is fixed or determinable – confirmed on the customer purchase order and then invoiced immediately upon shipment of the goods; and collectability is reasonably assured – our customers are long standing hospitals, ambulatory surgical centers and others that pass credit checks. The terms of our agreements with our customers are specified in written agreements. These written agreements, the purchase order and the matching invoice, constitute the persuasive evidence of the arrangements with our customers that are a precondition to the recognition of revenue. We undertake an evaluation of the creditworthiness of both new and, on a periodic basis, existing customers. Based on these reviews we determine whether collection of our prospective revenue is probable. We have adopted the provisions of Accounting Standards Update, or “ASU” 2014 09, 606 606 January 1, 2018 While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will not Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Investment Securities Readily marketable investments in debt and equity services are classified as available-for-sale and are reported at fair value with unrealized gains losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method. Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $58,872 2017 $73,249 2016. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $12,689 2017 $9,107 2016. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes (“ASC 740” 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Patents and Intellectual Property On January 25th, 2014, No. PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651, Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $563,000 Product Warranty Costs In 2017 2016, $6,209 $34,665 Segments The Company operates in two 2017 2016 $26,662 2017. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not

Note 2 - Development Stage Oper

Note 2 - Development Stage Operations	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Development Stage Enterprise Disclosures [Text Block]	NOTE 2 The Company was formed April 23, 2002. December 31, 2017, 6,943,283 $3,131.25.

Note 3 - Stockholders' Equity (

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 4 2018 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% Share Exchange Agreement With Helomics On January 11, 2018, 2,500,000 1,100,000 March 2018 $500,000 5% 25% $500,000 1,100,000 12 $8,000,000. 20% may Merger Agreement with Helomics On June 28, 2018, October 26, 2018, 9. not 7.5 1.1 20% 860,000 18 $7.6 18.7 $1.00 5.0 $1.00 75% $7.6 0.6 $1.00 23.7 14.2 $1.00 995,000 $0.01 597,000 $0.01 Under the Merger Agreement, completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics. On July 10 11, 2018, 250,000 $0.01, $1.18 750,000 $0.01, $1.17 Increases in Authorized Shares At a special meeting of the stockholders on January 29, 2017, 8,000,000 24,000,000 At the annual meeting on December 28, 2017, 24,000,000 50,000,000 $0.01 January 2, 2018. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On January 15, 2018, 50,000 $0.01 $0.97 four third fourth On March 12, 2018, 111,112 $0.01 $1.35 four third fourth For grants of stock option and warrants in 2018 2.33% 3.05% 0% 59% 66% 5 10 $0.4816 $1.0044 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 836,950 1.12 2,028,776 1.08 Expired (153,048 ) 2.00 (10,706 ) 199.55 Exercised - - (650,062 ) 1.00 Outstanding at September 30, 2018 3,448,885 $ 1.78 3,319,265 $ 4.55 At September 30, 2018, 2,522,848 $1.93 9.01 2,247,489 nine September 2018 September 2017 $800,322 7,908 $930,349 21 The following summarizes the status of options and warrants outstanding at September 30, 2018: Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.55 $ 0.965 3,000 9.63 $ 0.97 191,753 9.27 $ 1.01 149,110 9.38 $ 1.06 23,585 10.00 $ 1.10 86,958 9.71 $ 1.13 195,931 9.80 $ 1.15 21,740 9.84 $ 1.16 66,451 9.84 $ 1.18 30,000 9.86 $ 1.20 41,668 9.84 $ 1.21 30,000 9.86 $ 1.35 111,112 9.45 $ 1.454 17,200 9.01 $ 1.47 2,347,308 8.73 $ 2.10 14,286 8.50 $ 2.25 293 7.90 $ 2.42 20,640 7.84 $ 2.80 57,145 8.26 $ 3.75 3,998 5.24 $ 4.125 3,636 8.01 $ 4.1975 7,147 7.97 $ 4.25 3,529 7.50 $ 5.125 3,902 7.94 $ 65.75 190 7.06 $ 73.50 1,157 7.26 $ 77.50 2,323 6.75 $ 80.25 187 7.01 $ 86.25 232 6.50 $ 131.25 81 3.94 $ 148.125 928 4.47 $ 150.00 1,760 3.88 $ 162.50 123 6.26 $ 206.25 121 6.01 $ 248.4375 121 4.79 $ 262.50 130 4.79 $ 281.25 529 4.30 $ 318.75 3 4.60 $ 346.875 72 5.50 $ 431.25 306 5.44 $ 506.25 188 5.25 $ 596.25 42 5.00 3,448,885 Warrants $ 1.00 1,063,935 4.60 $ 1.07 697,946 4.10 $ 1.155 1,071,776 5.00 $ 2.25 385,000 3.32 $ 123.75 94,084 1.92 $ 243.75 2,529 0.84 $ 309.375 2,850 0.86 $ 309.50 222 1.10 $ 506.25 59 0.38 $ 609.375 862 0.34 3,319,265 At the annual meeting on December 28, 2017, 2012 5,000,000, December 4, 2017, 2012 2016 July 28, 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of September 30, 2018 Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,503,152 1.01 - 2.10 2018 836,950 0.91 - 1.35 Total 3,448,885 $0.91 – $596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 252,333 1.00 2017 1,082,946 1.07 - 2.25 2018 1,883,380 1.00 - 1.155 Total 3,319,265 $0.00 – $609.38	NOTE 3 2015 On August 31, 2015 ( 1,666,667 $9.00 $8.28 $0.72 8.00% $13.8 45 250,000 not 1% $70,000. On August 31, 2015, 228,343 1,895,010 75,801 1,895,010 7,580,040 Each Unit consisted of one $0.01 one four February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Certificate of Designation for Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants August 31, 2020. one $123.75 Holders may Total Shares = (A x Where: ☐ Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. ☐ A is the total number of shares with respect to which the Series A Warrant is then being exercised. ☐ B is the Black Scholes Value (as defined below). ☐ C is the closing bid price of the Common Stock as of two no may $0.43 The Black Scholes Value (as defined above) as of September 30, 2016 $4.319, September 30, 2016, $4.125. .40 6,141,115 September 30, 2016, 2,318,663 35,084 August 31, 2015 two $0.43 $4.319 September 30, 2016), 564 The Series A Warrants will not 4.99% 13 1934, In addition to (but not three 1 2 Unit Purchase Option The Company, in connection with the Offering, entered into a Unit Purchase Option Agreement, dated as of August 31, 2015 ( 5% 83,333 125% $11.25 May 2016 135,995 Series B Preferred Stock Each share of Series B Preferred Stock is convertible into one six not 4.99% no No Unit Exchange On February 4, 2014, $2,055,000 20,550 $0.01, $100 February 4, 2014. August 31, 2015, 228,343 3,391 3 9 August 31, 2015, no Redemption of Convertible Notes In connection with the closing of the Offering, $933,074 40% $1,548,792. 4. $167,031 Registered Exchange Offer for Warrants On March 25, 2016, $0.01 3,157,186 March 31, 2016, 10.05 may one 10.2 one April 21, 2016. 1,770,556 18,059,671 March 31, 2016 July 6, 2016 1,251,510 20,122 2016 On November 29, 2016, $1,983,337. 756,999 $2.62 five 756,999 six $4.46 $1,739,770. 2017 On January 19, 2017 1,750,000 $2.25 one 0.2 one $2.25 $3,937,500. 175,000 35,000 $0.01 $358,312. 2017 On November 30, 2017, 1,213,819 $1.071 606,910 $1.26 five one six $1,300,000 1.167 1,250,269 142,466 $189,285. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company has adopted ASC 718 Compensation-Stock Compensation 718" 718 January 1, 2006 January 1, 2006. January 1, 2006, not ASC 718 Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On July 1, 2016, 40,000 $0.01 $3.75 six fifth sixth On October 4, 2016, 400,000 $0.01, For grants of stock options and warrants in 2016 1.46% 2.45% 0% 59% 66% 5 10 $1.6329 $3.7195 On April 19, 2017, 400,000 $0.01, For grants of stock options and warrants in 2017 1.92% 2.40% 0% 59% 66% 5 10 $0.6541 $1.5489 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 At December 31, 2017, 1,728,264 $2.29 9.45 1,253,311 2017 2016 $1,892,159 $165,271, $1,139,172 24 The following summarizes the status of options and warrants outstanding at December 31, 2017: Range of Exercise Prices Shares Weighted Options: $ 1.01 124,358 10.00 $ 1.454 17,200 9.75 $ 1.47 2,456,226 9.48 $ 2.10 14,286 9.25 $ 2.25 293 8.65 $ 2.42 24,768 8.38 $ 2.80 57,145 9.01 $ 3.75 44,000 8.50 $ 4.125 3,636 8.75 $ 4.1975 7,147 8.72 $ 4.25 3,529 8.25 $ 5.125 3,902 8.69 $ 65.75 190 7.40 $ 73.50 1,157 8.01 $ 77.50 2,323 7.50 $ 80.25 187 7.75 $ 86.25 232 7.25 $ 131.25 81 4.69 $ 148.125 928 5.21 $ 150.00 1,760 4.63 $ 162.50 123 7.01 $ 206.25 121 6.75 $ 248.4375 121 5.54 $ 262.50 130 5.54 $ 281.25 529 5.04 $ 318.75 3 5.35 $ 346.875 72 6.25 $ 431.25 306 6.19 $ 506.25 188 6.00 $ 596.25 42 5.75 Total 2,764,983 Warrants $ 1.07 697,946 4.85 $ 2.25 385,000 4.06 $ 4.46 756,999 3.92 $ 93.75 2,255 0.19 $ 123.75 94,084 2.67 $ 150.00 4,114 0.20 $ 225.00 107 0.07 $ 243.75 2,529 1.59 $ 281.25 3,107 0.14 $ 309.375 2,850 1.61 $ 309.50 222 1.85 $ 337.50 178 0.46 $ 371.25 944 0.41 $ 506.25 59 1.12 $ 609.375 862 1.09 Total 1,951,257 Stock options and warrants expire on various dates from January 2018 December 2027. At a special meeting of stockholders held on September 15, 2016, 100,000,000 200,000,000 September 16, 2016, October 26, 2016, one twenty-five 1:25 200,000,000 8,000,000 5:00 October 27, 2016, October 28, 2016. may January 29, 2017. 8,000,000 24,000,000 December 28, 2017, January 2, 2018, 24,000,000 50,000,000 $0.01 2012 5,000,000, December 4, 2017, 2012 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of December 31, 2017 Stock Options: Year Shares Price 2011 173 281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 835 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,423 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 Total 2,764,983 $ 1.01 – 596.25 Warrants: Year Shares Price 2013 10,705 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 Total 1,951,257 $ 0.00 – 609.38

Note 4 - Notes Receivable

Note 4 - Notes Receivable	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, 8% two February 28, 2020. July 2018. not August, September October. September 27 28, 2018 October 2018, not not In October 2017, $600,000 December 2017, $67,512 fifty 50% March 2018, $500,000 833,333 5% 25%. In September 2018, $60,000 $163,468, September 30, 2018. October 2018, $907,500 9.	NOTE 4– In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, eight 8% two February 28, 2020. The Company advanced $600,000 8% April 30, 2018. December 2017, $67,512.10 fifty 50% March 2018, $500,000 833,333 5% 25%. $167,512.10

Note 5 - Loss Per Share

Note 5 - Loss Per Share	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 7 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,506,869 ) $ (992,095 ) $ (6,640,301 ) $ (4,877,542 ) Comprehensive loss (2,506,869 ) (992,095 ) (6,640,301 ) (4,877,542 ) Denominator: Weighted average common shares outstanding-basic 13,252,605 6,232,761 12,178,285 6,283,567 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 13,252,605 6,262,761 12,178,285 6,283,567 Loss per common share-basic and diluted $ (0.19 ) $ (0.16 ) $ (0.55 ) $ (0.78 ) ( 1 September 30, 2018 September 30, 2017 6,768,151 3,866,849, September 30, 2018 5,047,700. September 30, 2018 79,246.	NOTE 5 The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended December 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (7,746,593 ) $ (6,526,014 ) Other comprehensive income: Unrealized gain (loss) from marketable securities - 1,501 Comprehensive (loss) (7,746,593 ) (6,524,513 ) Denominator: Weighted average common shares outstanding-basic 6,362,989 2,823,345 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,362,989 2,823,345 Loss per common share-basic and diluted $ (1.22 ) $ (2.31 ) ( 1 December 31, 2017 December 31, 2016 4,716,240 1,036,744, December 31, 2017 79,246 647,819

Note 6 - Income Taxes

Note 6 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 6– The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Tax Reform Act was enacted December 22, 2017. January 1, 2018 34% 21%. There was no 100% no 100% During September 2013, 382 may September 2013, not At December 31, 2016, $30.9 2017, 382 2022 $13.0 December 31, 2016, 2022 2037 December 31, 2016, $10.7 $0.2 At December 31, 2017, $34.5 2018, 382 2022 $12.2 December 31, 2017, 2022 2037 December 31, 2017, $7.4 $0.2 The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. The components of deferred income taxes at December 31, 2017 December 31, 2016 December 31, 2017 December 31, 2016 Deferred Tax Asset: Net Operating Loss $ 7,393,100 $ 10,755,000 Other 215,843 189,000 Total Deferred Tax Asset 7,608,943 10,944,000 Less Valuation Allowance 7,608,943 10,944,000 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation

Note 7 - Rent Obligation	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	NOTE 7 Our corporate offices are located at 2915 900, 55121. November 22, 2017, second January 28, 2013. three February 1, 2018 January 31, 2021. 5,773 2,945 2,828 January 31, 2021. $66,122 $66,239 2017 2016, The Company’s rent obligation for the next four 2018 $ 39,000 2019 $ 40,000 2020 $ 42,000 2021 $ 3,000

Note 8 - Related Party Transa_2

Note 8 - Related Party Transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 8 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may In April 2018, one six $12,000 240,000 2012 six October 2018. April 2018 not	NOTE 8 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. In September 20, 2016, 400,000 four 100,000 November 1, 2016, November 2, 2016, April 2017,

Note 9 - Retirement Savings Pla

Note 9 - Retirement Savings Plans	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 9 We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401 2016, 2017, 100% 4.0% $29,952 $33,143 2017 2016. no 2017 2016.

Note 10 - Supplemental Cash Flo

Note 10 - Supplemental Cash Flow Data	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 10 Cash payments for interest were $0 $3 December 31, 2017 December 31, 2016,

Note 11 - Subsequent Events

Note 11 - Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 9 Private Placement of Convertible Secured Notes Effective as of September 28, 2018 ( two $2,297,727.50 October 3, 2018, $1,815,000, $2,000,000 September 30, 2018 one second $500,000 $2,865,909.00. 650,000 1,071,776 $1.155 second 1,336,805 sixth fifth The notes accrue interest at a rate of 8% twelve twelve $1.00 70% 20 may 2,678,328 Amended and Restated Merger Agreement On October 26, 2018, June 28, 2018. not 4 3.5 7.5 4 1.1 20% not one 4.	NOTE 11 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% On January 11, 2018, 2,500,000 1,100,000 $500,000 5% 25% $500,000 12 $8,000,000. 20% may On February 22, 2018, $667,512.50. $500,000 833,333 2,500,000 10,000,000 3,333,333 25% 13,333,333 $167,512.50 On February 27, 2018, may 25% 48Hour

Note 12 - Investment Securities

Note 12 - Investment Securities and Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Investment Securities and Other Comprehensive Income/(Loss) [Text Block]	NOTE 12 The cost and fair values of investment securities available-for-sale at December 31, 2016 December 31, 2016 Note Description Cost Gross Unrealized Gross Fair Value Mutual Funds $ 282,828 $ 1,501 $ - $ 284,329

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of September 30, 2018, 13,398,339 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, 4. 149,000 first 2018, The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $61,405,345. not $209,891 September 30, 2018 one not $1,815,000, September 28, 2018. first October 2018 September 28, 2018 Since inception to September 30, 2018, $36,490,000 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 $36,490,000 $3,405,052 2018 $2,755,000 $650,062 $5,685,000	Nature of Operations and Continuance of Operations The Company was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of December 31, 2017, 6,943,283 $.01 1 25 October 27, 2016. April 2009, 510 The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 not Since inception to December 31, 2017, $29,065,934 $2,055,000 $13,555,003 $1,739,770 $3,937,500 $358,312 $1,300,000 $5,685,000
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018, no 3 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not January 1, 2018. June 30, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. 2016 02 not	Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Deferral of the Effective Date,” 2016 08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.” 2017 13. December 15, 2017, not two 606. January 1, 2018 January 1, 2018, not In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, first 2017. In July 2015, No. 2015 11 , Inventory (Topic 330 December 15, 2016, first 2017. In November 2015, 2015 17, “Income Taxes (Topic 740 December 15, 2016 first 2017. In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not December 15, 2017, not In February 2016, No. 2016 02, (Topic 842” 2016 02” December 15, 2018. In March 2016, No. 2016 09, “Compensation (Topic 718 “ASU2016 09” 2016 09 December 15, 2016. first 2017. In August 2016, No. 2016 15, Statement of Cash Flows (Topic 230 December 15, 2017, not 2016 15 On December 22, 2017, 2017 34% 21%. We reviewed all other significant newly issued accounting pronouncements and determined they are either not no
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not	Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may not may not not
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.	Accounting Policies and Estimate The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three
Certificates of Deposit Policy [Policy Text Block]	Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one	Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1	Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first September 30, 2018 December 31, 2017 Finished goods $ 61,587 $ 62,932 Raw materials 157,610 141,028 Work-In-Process 58,958 61,085 Total $ 278,155 $ 265,045	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: September 30, 2018 December 31, 2017 Computers and office equipment $ 204,904 $ 183,528 Leasehold improvements 140,114 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 77,496 43,368 Total 531,469 361,486 Less: Accumulated depreciation 333,211 273,770 Total Fixed Assets, Net $ 198,258 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $26,120 $59,442 three nine September 30, 2018 $14,561 $44,764 three nine September 30, 2017.	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $58,872 2017 $73,249 2016.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was $38,387 $46,127 three nine September 30, 2018 $3,276 $9,067 three nine September 30, 2017.	Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $12,689 2017 $9,107 2016.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes (“ASC 740” 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651 As of July 11, 2018, #EP2948200	Patents and Intellectual Property On January 25th, 2014, No. PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one no no	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $563,000
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in two three nine September 30, 2018 2017 $4,195 $288 three September 2018 2017, $10,061 $25,188 first nine 2018 2017,	Segments The Company operates in two 2017 2016 $26,662 2017.
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not
Presentation of Taxes Collected From Customers, Policy [Policy Text Block]		Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.
Revenue Recognition, Shipping and Handling Cost, Policy [Policy Text Block]		Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.
Advertising Costs, Policy [Policy Text Block]		Advertising Advertising costs are expensed as incurred. Advertising expenses were $37,060 2017, $71,212 2016.
Research and Development Expense, Policy [Policy Text Block]		Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $289,000 $406,000 2017 2016,
Revenue Recognition, Policy [Policy Text Block]		Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Revenue Recognition and ASC 606 We recognize revenue when the following criteria are met: persuasive evidence of an arrangement exists – we receive both a signed purchase order and contract of terms and conditions confirming the sale from the customer; delivery has occurred – the goods are shipped from our warehouse and delivered and accepted by the customer; the selling price is fixed or determinable – confirmed on the customer purchase order and then invoiced immediately upon shipment of the goods; and collectability is reasonably assured – our customers are long standing hospitals, ambulatory surgical centers and others that pass credit checks. The terms of our agreements with our customers are specified in written agreements. These written agreements, the purchase order and the matching invoice, constitute the persuasive evidence of the arrangements with our customers that are a precondition to the recognition of revenue. We undertake an evaluation of the creditworthiness of both new and, on a periodic basis, existing customers. Based on these reviews we determine whether collection of our prospective revenue is probable. We have adopted the provisions of Accounting Standards Update, or “ASU” 2014 09, 606 606 January 1, 2018 While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will not
Marketable Securities, Policy [Policy Text Block]		Investment Securities Readily marketable investments in debt and equity services are classified as available-for-sale and are reported at fair value with unrealized gains losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method.
Receivables, Policy [Policy Text Block]		Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not
Standard Product Warranty, Policy [Policy Text Block]		Product Warranty Costs In 2017 2016, $6,209 $34,665

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2018 December 31, 2017 Finished goods $ 61,587 $ 62,932 Raw materials 157,610 141,028 Work-In-Process 58,958 61,085 Total $ 278,155 $ 265,045	December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3
Property, Plant and Equipment [Table Text Block]	September 30, 2018 December 31, 2017 Computers and office equipment $ 204,904 $ 183,528 Leasehold improvements 140,114 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 77,496 43,368 Total 531,469 361,486 Less: Accumulated depreciation 333,211 273,770 Total Fixed Assets, Net $ 198,258 $ 87,716	December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496

Note 2 - Equity Method Invest_2

Note 2 - Equity Method Investment (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Equity Method Investments [Table Text Block]	Helomics Holdings Corporation For the Nine Months Ended September 30, 2018 Revenue $ 623,662 Gross margin $ 441,370 Net loss from continuing operations $ (6,833,846 ) Net loss to investee $ (5,227,552 ) 1

Note 4 - Stockholders' Equity_2

Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 836,950 1.12 2,028,776 1.08 Expired (153,048 ) 2.00 (10,706 ) 199.55 Exercised - - (650,062 ) 1.00 Outstanding at September 30, 2018 3,448,885 $ 1.78 3,319,265 $ 4.55	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.55 $ 0.965 3,000 9.63 $ 0.97 191,753 9.27 $ 1.01 149,110 9.38 $ 1.06 23,585 10.00 $ 1.10 86,958 9.71 $ 1.13 195,931 9.80 $ 1.15 21,740 9.84 $ 1.16 66,451 9.84 $ 1.18 30,000 9.86 $ 1.20 41,668 9.84 $ 1.21 30,000 9.86 $ 1.35 111,112 9.45 $ 1.454 17,200 9.01 $ 1.47 2,347,308 8.73 $ 2.10 14,286 8.50 $ 2.25 293 7.90 $ 2.42 20,640 7.84 $ 2.80 57,145 8.26 $ 3.75 3,998 5.24 $ 4.125 3,636 8.01 $ 4.1975 7,147 7.97 $ 4.25 3,529 7.50 $ 5.125 3,902 7.94 $ 65.75 190 7.06 $ 73.50 1,157 7.26 $ 77.50 2,323 6.75 $ 80.25 187 7.01 $ 86.25 232 6.50 $ 131.25 81 3.94 $ 148.125 928 4.47 $ 150.00 1,760 3.88 $ 162.50 123 6.26 $ 206.25 121 6.01 $ 248.4375 121 4.79 $ 262.50 130 4.79 $ 281.25 529 4.30 $ 318.75 3 4.60 $ 346.875 72 5.50 $ 431.25 306 5.44 $ 506.25 188 5.25 $ 596.25 42 5.00 3,448,885 Warrants $ 1.00 1,063,935 4.60 $ 1.07 697,946 4.10 $ 1.155 1,071,776 5.00 $ 2.25 385,000 3.32 $ 123.75 94,084 1.92 $ 243.75 2,529 0.84 $ 309.375 2,850 0.86 $ 309.50 222 1.10 $ 506.25 59 0.38 $ 609.375 862 0.34 3,319,265	Range of Exercise Prices Shares Weighted Options: $ 1.01 124,358 10.00 $ 1.454 17,200 9.75 $ 1.47 2,456,226 9.48 $ 2.10 14,286 9.25 $ 2.25 293 8.65 $ 2.42 24,768 8.38 $ 2.80 57,145 9.01 $ 3.75 44,000 8.50 $ 4.125 3,636 8.75 $ 4.1975 7,147 8.72 $ 4.25 3,529 8.25 $ 5.125 3,902 8.69 $ 65.75 190 7.40 $ 73.50 1,157 8.01 $ 77.50 2,323 7.50 $ 80.25 187 7.75 $ 86.25 232 7.25 $ 131.25 81 4.69 $ 148.125 928 5.21 $ 150.00 1,760 4.63 $ 162.50 123 7.01 $ 206.25 121 6.75 $ 248.4375 121 5.54 $ 262.50 130 5.54 $ 281.25 529 5.04 $ 318.75 3 5.35 $ 346.875 72 6.25 $ 431.25 306 6.19 $ 506.25 188 6.00 $ 596.25 42 5.75 Total 2,764,983 Warrants $ 1.07 697,946 4.85 $ 2.25 385,000 4.06 $ 4.46 756,999 3.92 $ 93.75 2,255 0.19 $ 123.75 94,084 2.67 $ 150.00 4,114 0.20 $ 225.00 107 0.07 $ 243.75 2,529 1.59 $ 281.25 3,107 0.14 $ 309.375 2,850 1.61 $ 309.50 222 1.85 $ 337.50 178 0.46 $ 371.25 944 0.41 $ 506.25 59 1.12 $ 609.375 862 1.09 Total 1,951,257
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,503,152 1.01 - 2.10 2018 836,950 0.91 - 1.35 Total 3,448,885 $0.91 – $596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 252,333 1.00 2017 1,082,946 1.07 - 2.25 2018 1,883,380 1.00 - 1.155 Total 3,319,265 $0.00 – $609.38	Stock Options: Year Shares Price 2011 173 281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 835 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,423 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 Total 2,764,983 $ 1.01 – 596.25 Warrants: Year Shares Price 2013 10,705 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 Total 1,951,257 $ 0.00 – 609.38

Note 7 - Loss Per Share (Tables

Note 7 - Loss Per Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,506,869 ) $ (992,095 ) $ (6,640,301 ) $ (4,877,542 ) Comprehensive loss (2,506,869 ) (992,095 ) (6,640,301 ) (4,877,542 ) Denominator: Weighted average common shares outstanding-basic 13,252,605 6,232,761 12,178,285 6,283,567 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 13,252,605 6,262,761 12,178,285 6,283,567 Loss per common share-basic and diluted $ (0.19 ) $ (0.16 ) $ (0.55 ) $ (0.78 )	Year Ended December 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (7,746,593 ) $ (6,526,014 ) Other comprehensive income: Unrealized gain (loss) from marketable securities - 1,501 Comprehensive (loss) (7,746,593 ) (6,524,513 ) Denominator: Weighted average common shares outstanding-basic 6,362,989 2,823,345 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,362,989 2,823,345 Loss per common share-basic and diluted $ (1.22 ) $ (2.31 )

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies -2 (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2018 December 31, 2017 Finished goods $ 61,587 $ 62,932 Raw materials 157,610 141,028 Work-In-Process 58,958 61,085 Total $ 278,155 $ 265,045	December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3
Property, Plant and Equipment [Table Text Block]	September 30, 2018 December 31, 2017 Computers and office equipment $ 204,904 $ 183,528 Leasehold improvements 140,114 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 77,496 43,368 Total 531,469 361,486 Less: Accumulated depreciation 333,211 273,770 Total Fixed Assets, Net $ 198,258 $ 87,716	December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496

Note 3 - Stockholders' Equity_2

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 836,950 1.12 2,028,776 1.08 Expired (153,048 ) 2.00 (10,706 ) 199.55 Exercised - - (650,062 ) 1.00 Outstanding at September 30, 2018 3,448,885 $ 1.78 3,319,265 $ 4.55	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.55 $ 0.965 3,000 9.63 $ 0.97 191,753 9.27 $ 1.01 149,110 9.38 $ 1.06 23,585 10.00 $ 1.10 86,958 9.71 $ 1.13 195,931 9.80 $ 1.15 21,740 9.84 $ 1.16 66,451 9.84 $ 1.18 30,000 9.86 $ 1.20 41,668 9.84 $ 1.21 30,000 9.86 $ 1.35 111,112 9.45 $ 1.454 17,200 9.01 $ 1.47 2,347,308 8.73 $ 2.10 14,286 8.50 $ 2.25 293 7.90 $ 2.42 20,640 7.84 $ 2.80 57,145 8.26 $ 3.75 3,998 5.24 $ 4.125 3,636 8.01 $ 4.1975 7,147 7.97 $ 4.25 3,529 7.50 $ 5.125 3,902 7.94 $ 65.75 190 7.06 $ 73.50 1,157 7.26 $ 77.50 2,323 6.75 $ 80.25 187 7.01 $ 86.25 232 6.50 $ 131.25 81 3.94 $ 148.125 928 4.47 $ 150.00 1,760 3.88 $ 162.50 123 6.26 $ 206.25 121 6.01 $ 248.4375 121 4.79 $ 262.50 130 4.79 $ 281.25 529 4.30 $ 318.75 3 4.60 $ 346.875 72 5.50 $ 431.25 306 5.44 $ 506.25 188 5.25 $ 596.25 42 5.00 3,448,885 Warrants $ 1.00 1,063,935 4.60 $ 1.07 697,946 4.10 $ 1.155 1,071,776 5.00 $ 2.25 385,000 3.32 $ 123.75 94,084 1.92 $ 243.75 2,529 0.84 $ 309.375 2,850 0.86 $ 309.50 222 1.10 $ 506.25 59 0.38 $ 609.375 862 0.34 3,319,265	Range of Exercise Prices Shares Weighted Options: $ 1.01 124,358 10.00 $ 1.454 17,200 9.75 $ 1.47 2,456,226 9.48 $ 2.10 14,286 9.25 $ 2.25 293 8.65 $ 2.42 24,768 8.38 $ 2.80 57,145 9.01 $ 3.75 44,000 8.50 $ 4.125 3,636 8.75 $ 4.1975 7,147 8.72 $ 4.25 3,529 8.25 $ 5.125 3,902 8.69 $ 65.75 190 7.40 $ 73.50 1,157 8.01 $ 77.50 2,323 7.50 $ 80.25 187 7.75 $ 86.25 232 7.25 $ 131.25 81 4.69 $ 148.125 928 5.21 $ 150.00 1,760 4.63 $ 162.50 123 7.01 $ 206.25 121 6.75 $ 248.4375 121 5.54 $ 262.50 130 5.54 $ 281.25 529 5.04 $ 318.75 3 5.35 $ 346.875 72 6.25 $ 431.25 306 6.19 $ 506.25 188 6.00 $ 596.25 42 5.75 Total 2,764,983 Warrants $ 1.07 697,946 4.85 $ 2.25 385,000 4.06 $ 4.46 756,999 3.92 $ 93.75 2,255 0.19 $ 123.75 94,084 2.67 $ 150.00 4,114 0.20 $ 225.00 107 0.07 $ 243.75 2,529 1.59 $ 281.25 3,107 0.14 $ 309.375 2,850 1.61 $ 309.50 222 1.85 $ 337.50 178 0.46 $ 371.25 944 0.41 $ 506.25 59 1.12 $ 609.375 862 1.09 Total 1,951,257
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,503,152 1.01 - 2.10 2018 836,950 0.91 - 1.35 Total 3,448,885 $0.91 – $596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 252,333 1.00 2017 1,082,946 1.07 - 2.25 2018 1,883,380 1.00 - 1.155 Total 3,319,265 $0.00 – $609.38	Stock Options: Year Shares Price 2011 173 281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 835 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,423 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 Total 2,764,983 $ 1.01 – 596.25 Warrants: Year Shares Price 2013 10,705 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 Total 1,951,257 $ 0.00 – 609.38

Note 5 - Loss Per Share (Tables

Note 5 - Loss Per Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,506,869 ) $ (992,095 ) $ (6,640,301 ) $ (4,877,542 ) Comprehensive loss (2,506,869 ) (992,095 ) (6,640,301 ) (4,877,542 ) Denominator: Weighted average common shares outstanding-basic 13,252,605 6,232,761 12,178,285 6,283,567 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 13,252,605 6,262,761 12,178,285 6,283,567 Loss per common share-basic and diluted $ (0.19 ) $ (0.16 ) $ (0.55 ) $ (0.78 )	Year Ended December 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (7,746,593 ) $ (6,526,014 ) Other comprehensive income: Unrealized gain (loss) from marketable securities - 1,501 Comprehensive (loss) (7,746,593 ) (6,524,513 ) Denominator: Weighted average common shares outstanding-basic 6,362,989 2,823,345 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,362,989 2,823,345 Loss per common share-basic and diluted $ (1.22 ) $ (2.31 )

Note 6 - Income Taxes (Tables)

Note 6 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2017 December 31, 2016 Deferred Tax Asset: Net Operating Loss $ 7,393,100 $ 10,755,000 Other 215,843 189,000 Total Deferred Tax Asset 7,608,943 10,944,000 Less Valuation Allowance 7,608,943 10,944,000 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation (Table

Note 7 - Rent Obligation (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Rent Expense [Table Text Block]	2018 $ 39,000 2019 $ 40,000 2020 $ 42,000 2021 $ 3,000

Note 12 - Investment Securiti_2

Note 12 - Investment Securities and Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	December 31, 2016 Note Description Cost Gross Unrealized Gross Fair Value Mutual Funds $ 282,828 $ 1,501 $ - $ 284,329

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Feb. 22, 2017USD ($)	Nov. 29, 2016USD ($)	Aug. 31, 2015USD ($)	Oct. 31, 2018USD ($)	Jan. 31, 2018USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Jul. 11, 2018$ / shares	Jul. 10, 2018$ / shares	Mar. 31, 2018	Feb. 21, 2018$ / shares	Jan. 11, 2018	Jan. 02, 2018$ / shares	Dec. 28, 2017$ / shares	Apr. 19, 2017$ / shares	Oct. 04, 2016$ / shares	Dec. 31, 2015USD ($)
Common Stock, Shares, Outstanding, Ending Balance | shares						13,398,339		13,398,339		6,943,283	4,564,428	6,943,283	13,398,339
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.01		$ 0.01		$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01			$ 0.01	$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance						$ (61,405,345)		$ (61,405,345)		$ (54,765,045)	$ (47,018,451)	$ (54,765,045)	$ (61,405,345)
Cash and Cash Equivalents, at Carrying Value, Ending Balance						209,891	$ 765,704	209,891	$ 765,704	766,189	1,764,090	766,189	209,891										$ 4,856,232
Stockholders' Equity, Period Increase (Decrease), Total												29,065,934	36,490,000
Stock Issued During Period, Value, New Issues								2,755,087	3,421,188	3,421,188
Proceeds from Issuance or Sale of Equity, Total			$ 13,800,000					3,405,052
Proceeds from Warrant Exercises								650,062					650,062
Debt Instrument, Increase (Decrease), Net, Total												$ 5,685,000	$ 5,685,000
Depreciation, Total						26,120	14,561	59,442	44,764	58,872	73,249
Amortization of Intangible Assets, Total						$ 38,387	3,276	46,127	9,067	12,689	9,107
Income Tax Expense (Benefit), Total								$ 0	0	$ 0
Valuation Allowance Percentage						100.00%		100.00%		100.00%		100.00%	100.00%
Unrecognized Tax Benefits, Ending Balance						$ 0		$ 0		$ 0		$ 0	$ 0
Cash, Uninsured Amount						0		$ 0		$ 563,000		563,000	0
Number of Operating Segments								2		2
Non-US [Member]
Revenues, Total						$ 4,195	$ 288	$ 10,061	25,188	$ 26,662
Earliest Tax Year [Member]
Open Tax Year								2,014
Private Placement [Member]
Stock Issued During Period, Value, New Issues										1,213,819
IPO [Member]
Stock Issued During Period, Value, New Issues												13,555,003	13,555,003
Proceeds from Issuance or Sale of Equity, Total												3,937,500	3,937,500
The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues											$ 1,625,905
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs		$ 1,739,770										1,739,770	1,739,770
Proceeds from Issuance or Sale of Equity, Total		$ 1,983,337
Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues								$ 204,422	$ 393,750	$ 393,750
Proceeds from Issuance or Sale of Equity, Total	$ 358,312											358,312	358,312
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total					$ 2,755,000								2,755,000
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues												2,055,000	2,055,000
Series C Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues												$ 1,300,000	$ 1,300,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share | $ / shares																	$ 0.01		$ 0.01
Subsequent Event [Member] | The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total					$ 2,755,000
Subsequent Event [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreements [Member]
Proceeds from Convertible Debt				$ 1,815,000
Helomics Holding Corp. [Member]
Share Exchange Agreement, Potential Interest																25.00%
Helomics Holding Corp. [Member] | Subsequent Event [Member]
Share Exchange Agreement, Potential Interest																		25.00%

Note 1 - Summary of Significa_6

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Finished goods	$ 61,587	$ 62,932	$ 38,201
Raw materials	157,610	141,028	165,812
Work-In-Process	58,958	61,085	68,195
Total	$ 278,155	$ 265,045	$ 272,208

Note 1 - Summary of Significa_7

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	3 years	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years	7 years

Note 1 - Summary of Significa_8

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant, and Equipment Gross	$ 531,469	$ 361,486	$ 316,393
Less: Accumulated depreciation	333,211	273,770	214,897
Total Fixed Assets, Net	198,258	87,716	101,496
Office Equipment [Member]
Property, Plant, and Equipment Gross	204,904	183,528	164,318
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	140,114	25,635	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955	103,204
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 77,496	$ 43,368	$ 23,236

Note 2 - Equity Method Invest_3

Note 2 - Equity Method Investment (Details Textual) - Helomics Holding Corp. [Member] - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Feb. 27, 2018
Equity Method Investment, Ownership Percentage	75.00%	75.00%	80.00%
Equity Method Investment, Summarized Financial Information, Revenue		$ 623,662
Contract Research Organization and D-CHIP Artificial Intelligence Products [Member]
Equity Method Investment, Summarized Financial Information, Revenue	$ 31,000

Note 2 - Equity Method Invest_4

Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details) - Helomics Holding Corp. [Member]	9 Months Ended
	Sep. 30, 2018USD ($)
Revenue	$ 623,662
Gross margin	441,370
Net loss from continuing operations	(6,833,846)
Net loss to investee	$ (5,227,552)	[1]
[1]	The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 - February 27, 2018, and then at 75% for the remainder of the nine-month period at the current equity investment percentage owned by the Company.

Note 3 - Revenue Recognition (D

Note 3 - Revenue Recognition (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, Net, Current, Total	$ 238,598	$ 137,499	$ 38,919
Contract with Customer, Liability, Current	$ 15,306	$ 6,663	$ 7,998
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity_3

Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual)	Oct. 26, 2018USD ($)$ / sharesshares	Jul. 11, 2018$ / sharesshares	Jul. 10, 2018$ / sharesshares	Jun. 28, 2018shares	Mar. 12, 2018$ / sharesshares	Feb. 21, 2018USD ($)$ / sharesshares	Jan. 15, 2018$ / sharesshares	Jan. 11, 2018USD ($)shares	Feb. 22, 2017USD ($)	Jan. 19, 2017$ / sharesshares	Oct. 04, 2016$ / sharesshares	Jul. 01, 2016$ / sharesshares	Aug. 31, 2015USD ($)$ / shares	Jan. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Mar. 31, 2018USD ($)shares	Jan. 02, 2018$ / sharesshares	Dec. 28, 2017$ / sharesshares	Apr. 19, 2017$ / shares	Jan. 29, 2017shares	Oct. 27, 2016shares	Sep. 30, 2016$ / shares	Sep. 15, 2016shares	Sep. 14, 2016shares
Stock Issued During Period, Shares, New Issues											400,000
Share Price | $ / shares																												$ 4.125
Proceeds from Issuance or Sale of Equity, Total | $													$ 13,800,000			$ 3,405,052
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01	$ 0.01			$ 0.01					$ 0.01				$ 0.01	$ 0.01		$ 0.01	$ 0.01	$ 0.01	$ 0.01			$ 0.01	$ 0.01
Shares Issued, Price Per Share | $ / shares		$ 1.17	$ 1.18										$ 9
Stock Issued During Period, Shares, Issued for Services			250,000
Stock Issued During Period, Share, Issued in Escrow		750,000
Common Stock, Shares Authorized															50,000,000	50,000,000		50,000,000	50,000,000	50,000,000	50,000,000			50,000,000		24,000,000	8,000,000		200,000,000	100,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																0.00%		0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number															1,728,264	2,522,848		1,728,264		1,728,264	2,522,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares															$ 2.29	$ 1.93		$ 2.29		$ 2.29	$ 1.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																9 years 3 days		9 years 164 days
Class of Warrant or Right Number of Warrants Vested and Exercisable															1,253,311	2,247,489		1,253,311		1,253,311	2,247,489
Allocated Share-based Compensation Expense, Total | $																$ 800,322	$ 7,908	$ 1,892,159	$ 165,271
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $															$ 1,139,172	$ 930,349		$ 1,139,172		$ 1,139,172	$ 930,349
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost | $															$ 1,900,000
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share | $ / shares							$ 0.01					$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							50,000					40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares							$ 0.97					$ 3.75
Number of Equal Installments Options are Expected to Vest							4					6
Vice President of Sales and Marketing [Member]
Common Stock, Par or Stated Value Per Share | $ / shares					$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					111,112
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares					$ 1.35
Number of Equal Installments Options are Expected to Vest					4
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares															$ 609.38	$ 609.38		$ 609.38		$ 609.38	$ 609.38
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares																$ 596.25		$ 596.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																3.05%		2.40%	2.45%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																10 years		10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares																$ 1.0044		$ 1.5489	$ 3.7195
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares															$ 0	0		0		$ 0	$ 0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares																$ 0.91		$ 1.01
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																2.33%		1.92%	1.46%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																5 years		5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares																$ 0.4816		$ 0.6541	$ 1.6329
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																3 years		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																10 years		10 years
Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																3 years		3 years
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																		2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																								5,000,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.01																	$ 0.01
Common Stock, Shares Authorized																							50,000,000
Subsequent Event [Member] | Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																							5,000,000
Helomics Holding Corp. [Member]
Convertible Preferred Stock Held, Conversion Feature, Percent				20.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares				1,100,000
Helomics Holding Corp. [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares				7,500,000
Helomics Holding Corp. [Member] | Subsequent Event [Member]
Convertible Preferred Stock Held, Conversion Feature, Percent	20.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	1,100,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow	860,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow, Period	1 year 180 days
Notes Payable, Total | $	$ 7,600,000
Percentage of Holders of Acquiree's Promissory Note Agreeing to Merger	75.00%
Business Acquisition, Warrant Exchange Ratio	0.6
Helomics Holding Corp. [Member] | Subsequent Event [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues								1,100,000
Share Exchange Agreement, Shares Received								2,500,000
Share Exchange Agreement, Convertible Notes Receivable | $																						$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock																						5.00%
Share Exchange Agreement, Potential Interest																						25.00%
Share Exchange Agreement, Number of Shares Held in Escrow																						1,100,000
Share Exchange Agreement, Contingent Revenue, Minimum | $								$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent								20.00%
Helomics Holding Corp. [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues								1,100,000
Share Exchange Agreement, Shares Received								2,500,000
Share Exchange Agreement, Convertible Notes Receivable | $								$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock								5.00%														5.00%
Share Exchange Agreement, Potential Interest								25.00%
Share Exchange Agreement, Contingent Revenue, Minimum | $								$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent								20.00%
Helomics Warrants Held by Investors [Member] | Subsequent Event [Member] | Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	18,700,000
Helomics Warrants Held by Investors [Member] | Helomics Holding Corp. [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000,000
Precision Warrants [Member] | Helomics Holding Corp. [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1
Business Acquisition, Warrant Issued or Issuable, Exercise Price | $ / shares	$ 1
Business Acquisition, Equity Interest Issued or Issuable from Exchange of Warrants	23,700,000
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights	14,200,000
Helomics Warrants Held by Other Parties [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	597,000
Helomics Warrants Held by Other Parties [Member] | Subsequent Event [Member] | Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	995,000
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues														2,900,000
Share Price | $ / shares														$ 0.95
Proceeds from Issuance or Sale of Equity, Total | $														$ 2,755,000							$ 2,755,000
The 2018 Public Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues														2,900,000
Share Price | $ / shares														$ 0.95
Proceeds from Issuance or Sale of Equity, Total | $														$ 2,755,000
The 2018 Public Offering [Member] | Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit														0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right														1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 1
The 2018 Public Offering [Member] | Series E Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Issued per Unit														0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right														1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues						215,247
Proceeds from Issuance or Sale of Equity, Total | $									$ 358,312											$ 358,312	$ 358,312
Sale of Stock, Underwriter Option Term														45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase										175,000				290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase										35,000				87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares										$ 0.01				$ 0.001
Shares Issued, Price Per Share | $ / shares						$ 0.9497
Proceeds from Underwriter Shares Exercised, Net | $						$ 188,066
Stock Issued During Period, Underwriter Discount | $						$ 16,354
Underwriter Discount Percentage						8.00%
Over-Allotment Option [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues						215,247
Share Price | $ / shares						$ 0.9497
Sale of Stock, Underwriter Option Term														45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase														290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase														87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares														$ 0.001
Proceeds from Underwriter Shares Exercised, Net | $						$ 188,066
Stock Issued During Period, Underwriter Discount | $						$ 16,354
Underwriter Discount Percentage						8.00%

Note 4 - Stockholders' Equity_4

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares Outstanding (in shares)	2,764,983
Average Exercise Price Exercised (in dollars per share)			$ 65.75
Number of Shares Outstanding (in shares)	3,448,885	2,764,983
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	871,101	323,099
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 52.22	$ 128.40
Number of Shares Issued (in shares)	2,028,776	1,082,946	1,487,881
Average Exercise Price Issued (in dollars per share)	$ 1.08	$ 1.49	$ 0.71
Number of Shares Expired (in shares)	(10,706)	(2,790)
Average Exercise Price Expired (in dollars per share)	$ 199.55	$ 281.46
Number of Shares Exercised (in shares)	(650,062)		(939,879)
Average Exercise Price Exercised (in dollars per share)	$ 1
Number of Shares Outstanding (in shares)	3,319,265	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 4.55	$ 23.74	$ 52.22
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	165,643	31,350
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 11.22	$ 133.23
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	836,950	2,612,070	157,982
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.12	$ 1.45	$ 3.14
Number of Shares Expired (in shares)	(153,048)	(12,730)	(22,377)
Average Exercise Price Expired (in dollars per share)	$ 2	$ 10.39	$ 122.13
Number of Shares Exercised (in shares)			(1,312)
Average Exercise Price Exercised (in dollars per share)			$ 65.75
Number of Shares Outstanding (in shares)	3,448,885	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 1.78	$ 2	$ 11.22

Note 4 - Stockholders' Equity_5

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Shares, options (in shares)	3,448,885	2,764,983
Shares, warrants (in shares)	3,319,265	1,951,257
Warrant One [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1	$ 1.07
Shares, warrants (in shares)	1,063,935	697,946
Weighted average remaining life, warrants (Year)	4 years 219 days	4 years 310 days
Warrant Two [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07	$ 2.25
Shares, warrants (in shares)	697,946	385,000
Weighted average remaining life, warrants (Year)	4 years 36 days	4 years 21 days
Warrant Three [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.155	$ 4.46
Shares, warrants (in shares)	1,071,776	756,999
Weighted average remaining life, warrants (Year)	5 years	3 years 335 days
Warrant Four [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25	$ 93.75
Shares, warrants (in shares)	385,000	2,255
Weighted average remaining life, warrants (Year)	3 years 116 days	69 days
Warrant Five [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 123.75	$ 123.75
Shares, warrants (in shares)	94,084	94,084
Weighted average remaining life, warrants (Year)	1 year 335 days	2 years 244 days
Warrant Six [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 150
Shares, warrants (in shares)	2,529	4,114
Weighted average remaining life, warrants (Year)	306 days	73 days
Warrant Seven [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 309.375	$ 225
Shares, warrants (in shares)	2,850	107
Weighted average remaining life, warrants (Year)	313 days	25 days
Warrant Eight [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 309.50	$ 243.75
Shares, warrants (in shares)	222	2,529
Weighted average remaining life, warrants (Year)	1 year 36 days	1 year 215 days
Warrant Nine [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 506.25	$ 281.25
Shares, warrants (in shares)	59	3,107
Weighted average remaining life, warrants (Year)	138 days	51 days
Warrant Ten [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.375	$ 309.375
Shares, warrants (in shares)	862	2,850
Weighted average remaining life, warrants (Year)	124 days	1 year 222 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share)	$ 0.91	$ 1.01
Shares, options (in shares)	10,000	124,358
Weighted average remaining life, options (Year)	9 years 200 days	10 years
Stock Options Thirty-Three [Member]
Range of exercise prices, options (in dollars per share)	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	6 years 94 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share)	$ 0.965	$ 1.454
Shares, options (in shares)	3,000	17,200
Weighted average remaining life, options (Year)	9 years 229 days	9 years 273 days
Stock Options Thirty-Four [Member]
Range of exercise prices, options (in dollars per share)	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	6 years 3 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share)	$ 0.97	$ 1.47
Shares, options (in shares)	191,753	2,456,226
Weighted average remaining life, options (Year)	9 years 98 days	9 years 175 days
Stock Options Thirty-Five [Member]
Range of exercise prices, options (in dollars per share)	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	4 years 288 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share)	$ 1.01	$ 2.10
Shares, options (in shares)	149,110	14,286
Weighted average remaining life, options (Year)	9 years 138 days	9 years 91 days
Stock Options Thirty-Six [Member]
Range of exercise prices, options (in dollars per share)	$ 262.50
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	4 years 288 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share)	$ 1.06	$ 2.25
Shares, options (in shares)	23,585	293
Weighted average remaining life, options (Year)	10 years	8 years 237 days
Stock Options Thirty-Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	4 years 109 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share)	$ 1.10	$ 2.42
Shares, options (in shares)	86,958	24,768
Weighted average remaining life, options (Year)	9 years 259 days	8 years 138 days
Stock Options Thirty-Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	4 years 219 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 1.13	$ 2.80
Shares, options (in shares)	195,931	57,145
Weighted average remaining life, options (Year)	9 years 292 days	9 years 3 days
Stock Options Thirty-Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	5 years 182 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 1.15	$ 3.75
Shares, options (in shares)	21,740	44,000
Weighted average remaining life, options (Year)	9 years 306 days	8 years 182 days
Stock Options Forty [Member]
Range of exercise prices, options (in dollars per share)	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	5 years 160 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 1.16	$ 4.125
Shares, options (in shares)	66,451	3,636
Weighted average remaining life, options (Year)	9 years 306 days	8 years 273 days
Stock Options Forty-One [Member]
Range of exercise prices, options (in dollars per share)	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	5 years 91 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share)	$ 1.18	$ 4.1975
Shares, options (in shares)	30,000	7,147
Weighted average remaining life, options (Year)	9 years 313 days	8 years 262 days
Stock Options Forty-Two [Member]
Range of exercise prices, options (in dollars per share)	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	5 years
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share)	$ 1.20	$ 4.25
Shares, options (in shares)	41,668	3,529
Weighted average remaining life, options (Year)	9 years 306 days	8 years 91 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share)	$ 1.21	$ 5.125
Shares, options (in shares)	30,000	3,902
Weighted average remaining life, options (Year)	9 years 313 days	8 years 251 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.35	$ 65.75
Shares, options (in shares)	111,112	190
Weighted average remaining life, options (Year)	9 years 164 days	7 years 146 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.454	$ 73.50
Shares, options (in shares)	17,200	1,157
Weighted average remaining life, options (Year)	9 years 3 days	8 years 3 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.47	$ 77.50
Shares, options (in shares)	2,347,308	2,323
Weighted average remaining life, options (Year)	8 years 266 days	7 years 182 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.10	$ 80.25
Shares, options (in shares)	14,286	187
Weighted average remaining life, options (Year)	8 years 182 days	7 years 273 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.25	$ 86.25
Shares, options (in shares)	293	232
Weighted average remaining life, options (Year)	7 years 328 days	7 years 91 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.42	$ 131.25
Shares, options (in shares)	20,640	81
Weighted average remaining life, options (Year)	7 years 306 days	4 years 251 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.80	$ 148.125
Shares, options (in shares)	57,145	928
Weighted average remaining life, options (Year)	8 years 94 days	5 years 76 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share)	$ 3.75	$ 150
Shares, options (in shares)	3,998	1,760
Weighted average remaining life, options (Year)	5 years 87 days	4 years 229 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share)	$ 4.125	$ 162.50
Shares, options (in shares)	3,636	123
Weighted average remaining life, options (Year)	8 years 3 days	7 years 3 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share)	$ 4.1975	$ 206.25
Shares, options (in shares)	7,147	121
Weighted average remaining life, options (Year)	7 years 354 days	6 years 273 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share)	$ 4.25	$ 248.4375
Shares, options (in shares)	3,529	121
Weighted average remaining life, options (Year)	7 years 182 days	5 years 197 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share)	$ 5.125	$ 262.50
Shares, options (in shares)	3,902	130
Weighted average remaining life, options (Year)	7 years 343 days	5 years 197 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share)	$ 65.75	$ 281.25
Shares, options (in shares)	190	529
Weighted average remaining life, options (Year)	7 years 21 days	5 years 14 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share)	$ 73.50	$ 318.75
Shares, options (in shares)	1,157	3
Weighted average remaining life, options (Year)	7 years 94 days	5 years 127 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 77.50	$ 346.875
Shares, options (in shares)	2,323	72
Weighted average remaining life, options (Year)	6 years 273 days	6 years 91 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 80.25	$ 431.25
Shares, options (in shares)	187	306
Weighted average remaining life, options (Year)	7 years 3 days	6 years 69 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 86.25	$ 506.25
Shares, options (in shares)	232	188
Weighted average remaining life, options (Year)	6 years 182 days	6 years
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share)	$ 131.25	$ 596.25
Shares, options (in shares)	81	42
Weighted average remaining life, options (Year)	3 years 343 days	5 years 273 days
Stock Options Thirty-One [Member]
Range of exercise prices, options (in dollars per share)	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	4 years 171 days
Stock Options Thirty-Two [Member]
Range of exercise prices, options (in dollars per share)	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	3 years 321 days

Note 4 - Stockholders' Equity_6

Note 4 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Shares, options (in shares)	3,448,885	2,764,983
Shares, warrants (in shares)	3,319,265	1,951,257
Minimum [Member]
Price, options (in dollars per share)	$ 0.91	$ 1.01
Warrant exercises, exercise price per share (in dollars per share)	0	0
Maximum [Member]
Price, options (in dollars per share)	596.25	596.25
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38	$ 609.38
Warrants 2014 [Member]
Shares, warrants (in shares)	6,455	6,455
Warrants 2014 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 243.75
Warrants 2014 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares)	94,151	94,152
Warrants 2015 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0	$ 0
Warrants 2015 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares)	252,333	756,999
Warrant exercises, exercise price per share (in dollars per share)	$ 1	$ 4.46
Warrants 2017 [Member]
Shares, warrants (in shares)	1,082,946	1,082,946
Warrants 2017 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07	$ 1.07
Warrants 2017 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares)	1,883,380
Warrants 2018 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Warrants 2018 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.155
Stock Options 2011 [Member]
Shares, options (in shares)	173	173
Price, options (in dollars per share)	$ 281.25	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares)	1,841	1,841
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 131.25	$ 131.25
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 150	$ 150
Stock Options 2013 [Member]
Shares, options (in shares)	1,553	1,553
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 148.13	$ 148.13
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 596.25	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares)	836	835
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 162.50	$ 162.50
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 431.25	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares)	4,088	4,088
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 65.75	$ 65.75
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 86.25	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares)	100,292	144,423
Stock Options 2016 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 2.25	$ 2.25
Stock Options 2016 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 5.13	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares)	2,503,152	2,612,070
Stock Options 2017 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.01	$ 1.01
Stock Options 2017 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 2.10	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares)	836,950
Stock Options 2018 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 0.91
Stock Options 2018 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 1.35

Note 5 - Notes Receivable (Deta

Note 5 - Notes Receivable (Details Textual) - USD ($)	Feb. 22, 2018	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Nov. 30, 2017	Oct. 31, 2017	Feb. 21, 2018	Jan. 11, 2018	Jul. 31, 2017
Advance to Helomics [Member]
Notes Receivable, Interest Rate, Stated Percentage						8.00%
Payments to Acquire Notes Receivable						$ 600,000	$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable			$ 60,000		$ 67,512.10
Lease to Purchase Equipment, Down Payment, Percentage					50.00%
Advances to De Lage Landen [Member] | Subsequent Event [Member]
Payments to Acquire Notes Receivable		$ 907,500
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage				8.00%						8.00%
Financing Receivable, Net, Total				$ 1,112,524	$ 1,070,000
Notes Receivable, Term				2 years
CytoBioscience [Member] | Promissory Notes Receivable [Member] | Subsequent Event [Member]
Notes Receivable, Interest Rate, Stated Percentage				8.00%
Financing Receivable, Net, Total				$ 1,112,524
Notes Receivable, Term				2 years
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total			$ 163,468
Share Exchange Agreement, Outstanding Receivables, Amount Converted				$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables				833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock				5.00%
Investment, Ownership Percent				25.00%
Helomics Holding Corp. [Member] | Subsequent Event [Member]
Financing Receivable, Net, Total	$ 167,512.50			$ 167,512.10				$ 667,512.50
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000			$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333			833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock				5.00%					5.00%
Investment, Ownership Percent	25.00%			25.00%

Note 6 - Convertible Debt and_2

Note 6 - Convertible Debt and Derivative Liability (Details Textual)	Oct. 26, 2018USD ($)shares	Oct. 03, 2018USD ($)$ / sharesshares	Oct. 04, 2016shares	Sep. 30, 2018USD ($)yr$ / shares	Sep. 28, 2018USD ($)	Dec. 31, 2017$ / shares
Stock Issued During Period, Shares, New Issues | shares			400,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 609.38		$ 609.38
Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Fair Value per Warrant | $ / shares				$ 0.5361
Warrants and Rights Outstanding				$ 574,631
Warrants in Connection with Convertible Promissory Note [Member] | Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0.0294
Warrants in Connection with Convertible Promissory Note [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr				5
Warrants in Connection with Convertible Promissory Note [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input				0.59
Subsequent Event [Member] | Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	1,336,805	1,071,776
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 1.155
Warrants and Rights Outstanding, Term		5 years
Subsequent Event [Member] | Inducement Common Stock Issued in Connection with Convertible Promissory Notes [Member]
Stock Issued During Period, Shares, New Issues | shares		650,000
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount					$ 2,297,727.50
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Subsequent Event [Member]
Debt Instrument, Face Amount	$ 2,865,909
Proceeds from Notes Payable, Net		$ 1,815,000
Proceeds from Notes Payable, Total	$ 500,000	$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Term		1 year
Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock		70.00%
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares | shares		2,678,328
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Subsequent Event [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 1

Note 7 - Loss Per Share (Detail

Note 7 - Loss Per Share (Details Textual) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,768,151	3,866,849	4,716,240	1,036,744
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,047,700
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 7 - Loss Per Share - Share

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)	3 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2018		Sep. 30, 2017		Sep. 30, 2018		Sep. 30, 2017		Dec. 31, 2017		Dec. 31, 2016
Net loss available in basic and diluted calculation	$ (2,506,869)		$ (992,095)		$ (6,640,301)		$ (4,877,542)		$ (7,746,593)		$ (6,526,014)
Comprehensive loss	$ (2,506,869)		$ (992,095)		$ (6,640,301)		$ (4,877,542)		$ (7,746,593)		$ (6,524,513)
Weighted average common shares outstanding-basic (in shares)	13,252,605		6,232,761		12,178,285		6,283,567		6,362,989		2,823,345
Effect of diluted stock options, warrants and preferred stock (1) (in shares)		[1]		[1]		[1]		[1]		[2]		[2]
Weighted average common shares outstanding-basic (in shares)	13,252,605		6,262,761		12,178,285		6,283,567
Loss per common share - basic and diluted (in dollars per share)	$ (0.19)		$ (0.16)		$ (0.55)		$ (0.78)		$ (1.22)		$ (2.31)
[1]	The number of shares underlying options and warrants outstanding as of September 30, 2018 and September 30, 2017 are 6,768,151 and 3,866,849, respectively. The number of shares underlying the convertible debt as of September 30, 2018 is 5,047,700. The number of shares underlying the preferred stock as of September 30, 2018 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
[2]	The number of shares underlying options and warrants outstanding as of December 31, 2017 and December 31, 2016 are 4,716,240 and 1,036,744, respectively. The number of shares underlying the preferred stock as of December 31, 2017 is 79,246 for Series B Convertible and 647,819 for Series C Convertible. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 8 - Related Party Transa_3

Note 8 - Related Party Transactions (Details Textual) - Director [Member]	1 Months Ended
	Apr. 30, 2018USD ($)shares
Related Party Transaction, Monthly Cash Payment | $	$ 12,000
Restricted Stock Units (RSUs) [Member] | Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares	240,000

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details Textual) - USD ($)	Oct. 26, 2018	Oct. 03, 2018	Jun. 28, 2018	Oct. 04, 2016	Sep. 30, 2018	Sep. 28, 2018	Dec. 31, 2017
Stock Issued During Period, Shares, New Issues				400,000
Helomics Holding Corp. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			1,100,000
Convertible Preferred Stock Held, Conversion Feature, Percent			20.00%
Helomics Holding Corp. [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			7,500,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 609.38		$ 609.38
Subsequent Event [Member] | Helomics Holding Corp. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	1,100,000
Convertible Preferred Stock Held, Conversion Feature, Percent	20.00%
Subsequent Event [Member] | Helomics Holding Corp. [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000
Subsequent Event [Member] | Helomics Holding Corp. [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	4,000,000
Subsequent Event [Member] | Helomics Holding Corp. [Member] | Series D Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,500,000
Subsequent Event [Member] | Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,336,805	1,071,776
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.155
Warrants and Rights Outstanding, Term		5 years
Subsequent Event [Member] | Inducement Common Stock Issued in Connection with Convertible Promissory Notes [Member]
Stock Issued During Period, Shares, New Issues		650,000
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount						$ 2,297,727.50
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Subsequent Event [Member]
Debt Instrument, Face Amount	$ 2,865,909
Proceeds from Notes Payable, Net		$ 1,815,000
Proceeds from Notes Payable, Total	$ 500,000	$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Term		1 year
Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock		70.00%
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares		2,678,328
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Subsequent Event [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price		$ 1

Note 1 - Summary of Significa_9

Note 1 - Summary of Significant Accounting Policies -2 (Details Textual)	Feb. 22, 2017USD ($)	Nov. 29, 2016USD ($)	Oct. 27, 2016	Aug. 31, 2015USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Dec. 31, 2018	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Jul. 11, 2018$ / shares	Jul. 10, 2018$ / shares	Feb. 21, 2018$ / shares	Dec. 28, 2017$ / shares	Apr. 19, 2017$ / shares	Oct. 04, 2016$ / shares
Common Stock, Shares, Outstanding, Ending Balance | shares					13,398,339		13,398,339			6,943,283	4,564,428	6,943,283	13,398,339
Common Stock, Par or Stated Value Per Share | $ / shares					$ 0.01		$ 0.01			$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Stockholders' Equity, Period Increase (Decrease), Total												$ 29,065,934	$ 36,490,000
Stock Issued During Period, Value, New Issues							$ 2,755,087	$ 3,421,188		$ 3,421,188
Proceeds from Issuance or Sale of Equity, Total				$ 13,800,000			3,405,052
Debt Instrument, Increase (Decrease), Net, Total												5,685,000	5,685,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent										34.00%
Advertising Expense										$ 37,060	$ 71,212
Research and Development Expense, Total										289,000	406,000
Depreciation, Total					$ 26,120	$ 14,561	59,442	44,764		58,872	73,249
Amortization of Intangible Assets, Total					38,387	3,276	46,127	9,067		12,689	9,107
Unrecognized Tax Benefits, Ending Balance					0		0			0		0	0
Cash, Uninsured Amount					0		$ 0			563,000		563,000	0
Product Warranty Expense										$ 6,209	34,665
Number of Operating Segments							2			2
Non-US [Member]
Revenues, Total					$ 4,195	$ 288	$ 10,061	25,188		$ 26,662
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent									21.00%
Private Placement [Member]
Stock Issued During Period, Value, New Issues										1,213,819
IPO [Member]
Stock Issued During Period, Value, New Issues												13,555,003	13,555,003
Proceeds from Issuance or Sale of Equity, Total												3,937,500	3,937,500
The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues											$ 1,625,905
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs		$ 1,739,770										1,739,770	1,739,770
Proceeds from Issuance or Sale of Equity, Total		$ 1,983,337
Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues							$ 204,422	$ 393,750		$ 393,750
Proceeds from Issuance or Sale of Equity, Total	$ 358,312											358,312	358,312
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues												2,055,000	2,055,000
Series C Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues												$ 1,300,000	$ 1,300,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			25

Note 1 - Summary of Signific_10

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Finished goods	$ 61,587	$ 62,932	$ 38,201
Raw materials	157,610	141,028	165,812
Work-In-Process	58,958	61,085	68,195
Total	$ 278,155	$ 265,045	$ 272,208

Note 1 - Summary of Signific_11

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	3 years	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years	7 years

Note 1 - Summary of Signific_12

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Net (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant, and Equipment Gross	$ 531,469	$ 361,486	$ 316,393
Less: Accumulated depreciation	333,211	273,770	214,897
Total Fixed Assets, Net	198,258	87,716	101,496
Office Equipment [Member]
Property, Plant, and Equipment Gross	204,904	183,528	164,318
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	140,114	25,635	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955	103,204
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 77,496	$ 43,368	$ 23,236

Note 2 - Development Stage Op_2

Note 2 - Development Stage Operations (Details Textual) - $ / shares	Dec. 31, 2017	Sep. 30, 2016
Common Stock, Shares, Issued, Total	6,943,283
Share Price		$ 4.125
Common Stock [Member] | Maximum [Member]
Share Price	$ 3,131.25

Note 3 - Stockholders' Equity_3

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual)	Feb. 21, 2018$ / sharesshares	Jan. 15, 2018$ / sharesshares	Nov. 30, 2017USD ($)$ / sharesshares	Apr. 19, 2017$ / sharesshares	Feb. 22, 2017USD ($)	Jan. 19, 2017USD ($)$ / sharesshares	Nov. 29, 2016USD ($)$ / sharesshares	Oct. 27, 2016shares	Oct. 04, 2016$ / sharesshares	Jul. 01, 2016$ / sharesshares	Mar. 31, 2016shares	Aug. 31, 2015USD ($)$ / sharesshares	Feb. 04, 2014USD ($)$ / sharesshares	Jan. 31, 2018$ / sharesshares	May 31, 2016shares	Dec. 31, 2017USD ($)$ / sharesshares	Jul. 06, 2016shares	Jun. 30, 2018USD ($)shares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)shares	Sep. 30, 2016$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Jul. 11, 2018$ / shares	Jul. 10, 2018$ / shares	Jan. 02, 2018$ / sharesshares	Dec. 28, 2017$ / sharesshares	Jan. 29, 2017shares	Sep. 15, 2016shares	Sep. 14, 2016shares	Apr. 21, 2016shares	Mar. 25, 2016$ / sharesshares
Shares Issued, Price Per Share | $ / shares												$ 9														$ 1.17	$ 1.18
Underwriter Price | $ / shares												8.28
Underwriting Discount | $ / shares												$ 0.72
Underwriting Commission												8.00%
Proceeds from Issuance or Sale of Equity, Total | $												$ 13,800,000							$ 3,405,052
Option Granted to Underwriter to Purchase Additional Units Period												45 days
Option Granted to Underwriter to Purchase Additional Units Number of Units Granted												250,000
Underwriting Agreement Non-accountable Expense Allowance Percentage												1.00%
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.01			$ 0.01					$ 0.01							$ 0.01			$ 0.01			$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01
Share Price | $ / shares																					$ 4.125
Class of Warrant or Right, Outstanding																1,951,257			3,319,265			1,951,257		1,951,257	3,319,265
Stock Issued During Period, Value, New Issues | $																			$ 2,755,087	$ 3,421,188		$ 3,421,188
Stock Issued During Period, Shares, New Issues									400,000
Proceeds from Issuance of Convertible Preferred Stock | $																						$ 1,300,001
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																			0.00%			0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum																						59.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum																						66.00%	66.00%
Reverse Shares Issued for Escrow Pursuant to Termination of Agreement, Shares				400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number																1,728,264			2,522,848			1,728,264		1,728,264	2,522,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares																$ 2.29			$ 1.93			$ 2.29		$ 2.29	$ 1.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																			9 years 3 days			9 years 164 days
Class of Warrant or Right Number of Warrants Vested and Exercisable																1,253,311			2,247,489			1,253,311		1,253,311	2,247,489
Allocated Share-based Compensation Expense, Total | $																			$ 800,322	7,908		$ 1,892,159	$ 165,271
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $																$ 1,139,172			$ 930,349			$ 1,139,172		$ 1,139,172	$ 930,349
Common Stock, Shares Authorized								8,000,000								50,000,000			50,000,000			50,000,000	50,000,000	50,000,000	50,000,000				50,000,000	24,000,000	200,000,000	100,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost | $																$ 1,900,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio								25
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01								$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		50,000								40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares		$ 0.97								$ 3.75
Number of Equal Installments Options are Expected to Vest		4								6
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																						2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																													5,000,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share | $ / shares	0.01																											$ 0.01
Common Stock, Shares Authorized																												50,000,000
Subsequent Event [Member] | Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																												5,000,000
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $							$ 1,983,337
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 4.46
Share Price | $ / shares							$ 2.62
Stock Issued During Period, Value, New Issues | $																							$ 1,625,905
Stock Issued During Period, Shares, New Issues							756,999
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							756,999
Class of Warrant or Right Term							5 years
Class of Warrant or Right, Vesting Period							180 days
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $							$ 1,739,770																	$ 1,739,770	$ 1,739,770
The 2017 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $						$ 3,937,500
Share Price | $ / shares						$ 2.25
Stock Issued During Period, Shares, New Issues						1,750,000
Share Per Each Unit						1
Over-Allotment Option [Member]
Shares Issued, Price Per Share | $ / shares	$ 0.9497
Proceeds from Issuance or Sale of Equity, Total | $					$ 358,312																			$ 358,312	$ 358,312
Stock Issued During Period, Value, New Issues | $																			$ 204,422	393,750		$ 393,750
Stock Issued During Period, Shares, New Issues	215,247
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase						175,000								290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase						35,000								87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares						$ 0.01								$ 0.001
Over-Allotment Option [Member] | Subsequent Event [Member]
Share Price | $ / shares	$ 0.9497
Stock Issued During Period, Shares, New Issues	215,247
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase														290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase														87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares														$ 0.001
Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.26
Stock Issued During Period, Value, New Issues | $																						$ 1,213,819
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			606,910
Class of Warrant or Right Term			5 years 182 days
Class of Warrant or Right, Vesting Period			180 days
Proceeds from Issuance of Convertible Preferred Stock | $			$ 1,300,000
Conversion from Series C Convertible Preferred Stock to Common Stock [Member] | Subsequent Event [Member]
Convertible Preferred Stock, Shares Issued upon Conversion																		1.167
Conversion of Stock, Shares Issued																		1,250,269
The Convertible Notes [Member]
Debt Instrument Redemption Principal Amount | $												$ 933,074
Debt Instrument Redemption Premium Percentage												40.00%
Debt Instrument Redemption Price | $												$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates | $												$ 167,031
Series B Convertible Preferred Stock [Member]
Beneficial Ownership Limitation Percentage																						4.99%
Stock Issued During Period, Value, New Issues | $													$ 2,055,000
Stock Issued During Period, Shares, New Issues													20,550
Preferred Stock Par Value | $ / shares													$ 0.01
Preferred Stock Stated Value | $ / shares													$ 100
Preferred Stock, Shares Outstanding, Ending Balance																79,246			79,246			79,246	79,246	79,246	79,246
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance												0
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance																647,819			0			647,819	0	647,819	0
Series A Warrants [Member] | Exchange Offer [Member]
Stock to be Issued for Exchange Offer, Shares, Maximum																																		3,157,186
Cashless Exercise of Common Stock Warrants, Total											10.05
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																	1,770,556
Exchange from Series B Warrants to Warrant Shares [Member] | Exchange Offer [Member]
Common Stock, Par or Stated Value Per Share | $ / shares																																		$ 0.01
Series B Warrants [Member] | Exchange Offer [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right											1
Class of Warrant or Right Exercised During Period																	1,251,510
Stock Issued During Period, Shares, Warrants Exercised																	20,122
Cashless Exercise of Common Stock Warrants, Total											10.2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																	18,059,671
Series D Warrants [Member] | The 2017 Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 2.25
Class of Warrant or Right, Issued per Unit						0.2
Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities																			589,747			660,522
Stock Issued During Period, Value, New Issues | $																			$ 29,000	$ 17,500		$ 17,500
Stock Issued During Period, Shares, New Issues																			2,900,000	1,750,000		1,750,000
Reverse Shares Issued for Escrow Pursuant to Termination of Agreement, Shares																				400,000		400,000
Common Stock [Member] | The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues | $																							$ 7,570
Stock Issued During Period, Shares, New Issues																							756,999
Common Stock [Member] | Over-Allotment Option [Member]
Shares Issued, Price Per Share | $ / shares																			$ 0.9497						$ 0.9497
Stock Issued During Period, Value, New Issues | $																			$ 2,153	$ 1,750		$ 1,750
Stock Issued During Period, Shares, New Issues																			215,247	175,000		175,000
Common Stock [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised																							2,318,663
Common Stock [Member] | Series B Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised																							628,237
Preferred Stock [Member]
Stock Issued During Period, Value, New Issues | $
Preferred Stock [Member] | Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues | $
Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues | $																						$ 12,138
Preferred Stock [Member] | Series C Convertible Preferred Stock [Member] | Subsequent Event [Member]
Stock Redeemed or Called During Period, Shares																		142,466
Payments for Repurchase of Convertible Preferred Stock | $																		$ 189,285
Preferred Stock [Member] | Series C Convertible Preferred Stock [Member] | Private Placement [Member]
Shares Issued, Price Per Share | $ / shares			$ 1.071
Stock Issued During Period, Shares, New Issues			1,213,819
Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit												1
Common Stock, Par or Stated Value Per Share | $ / shares												$ 0.01
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																					0.4
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																$ 123.75						$ 123.75		$ 123.75
Cash Less Exercise Formula Definition of Letter C in the Formula Closing Bid Price Number of Trading Days Prior to the Time of Exercise																						2 days
Cash Less Exercise Formula Closing Bid Price Per Share Minimum to Be Used in the Formula | $ / shares																$ 0.43						$ 0.43		$ 0.43
Warrants Option to Settle in Cash Fair Value Disclosure | $ / shares																					$ 4.319
Class of Warrant or Right Exercised During Period																					6,141,115
Stock Issued During Period, Shares, Warrants Exercised																					2,318,663
Class of Warrant or Right, Outstanding																35,084						35,084		35,084
Class of Warrant or Right Cash less Exercise Common Stock Price That Would Result in a Dilutive Exercise | $ / shares																$ 0.43						$ 0.43		$ 0.43
Beneficial Ownership Limitation Percentage																						4.99%
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member] | Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member]
Stock Issued During Period, Shares, Warrants Exercised																					564
Corporate Stock Transfer Inc. [Member] | Series B Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit												1
Corporate Stock Transfer Inc. [Member] | Series A Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit												4
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right												1
Maximum [Member]
Underwriting Agreement Expenses Agreed to Reimburse the Underwriter | $												$ 70,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																609.38			$ 609.38			$ 609.38		609.38	609.38
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares																			$ 596.25			$ 596.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																			3.05%			2.40%	2.45%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																			10 years			10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares																			$ 1.0044			$ 1.5489	$ 3.7195
Maximum [Member] | Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																			3 years			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																			10 years			10 years
Maximum [Member] | Common Stock [Member]
Share Price | $ / shares																3,131.25						$ 3,131.25		3,131.25
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																$ 0			$ 0			0		$ 0	$ 0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares																			$ 0.91			$ 1.01
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																			2.33%			1.92%	1.46%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																			5 years			5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares																			$ 0.4816			$ 0.6541	$ 1.6329
Minimum [Member] | Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																			3 years			3 years
Exchange Units [Member]
Unit Purchase Option Units Sold												1,666,667
Stock Issued During Period, Shares, Conversion of Convertible Securities												1,895,010
Exchange Units [Member] | Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												3,391
Exchange Units [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												7,580,040
Exchange Units [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												75,801
Exchange Units [Member] | Series B Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												1,895,010
Exchange Units [Member] | Corporate Stock Transfer Inc. [Member]
Unit Purchase Option Units Issued												228,343
Stock Issued During Period, Shares, Conversion of Convertible Securities															135,995
Unit Purchase Option Number of Units Available for Underwriter to Purchase, Percentage												5.00%
Unit Purchase Option Number of Units Available For Underwriter to Purchase												83,333
Unit Purchase Option Exercise Price, Percentage												125.00%
Unit Purchase Option Exercise Price | $ / shares												$ 11.25
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																			836,950			2,612,070	157,982
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares																			$ 1.12			$ 1.45	$ 3.14
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																						2 years

Note 3 - Stockholders' Equity_4

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares Outstanding (in shares)	2,764,983
Options exercise price (in dollars per share)			$ 65.75
Number of Shares Outstanding (in shares)	3,448,885	2,764,983
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	871,101	323,099
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 52.22	$ 128.40
Number of Shares Issued (in shares)	2,028,776	1,082,946	1,487,881
Average Exercise Price Issued (in dollars per share)	$ 1.08	$ 1.49	$ 0.71
Number of Shares Expired (in shares)	(10,706)	(2,790)
Average Exercise Price Expired (in dollars per share)	$ 199.55	$ 281.46
Number of Shares Exercised (in shares)	(650,062)		(939,879)
Average Exercise Price Exercised (in dollars per share)	$ 1
Number of Shares Outstanding (in shares)	3,319,265	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 4.55	$ 23.74	$ 52.22
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	165,643	31,350
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 11.22	$ 133.23
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	836,950	2,612,070	157,982
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.12	$ 1.45	$ 3.14
Number of Shares Expired (in shares)	(153,048)	(12,730)	(22,377)
Average Exercise Price Expired (in dollars per share)	$ 2	$ 10.39	$ 122.13
Number of Shares Exercised (in shares)			(1,312)
Options exercise price (in dollars per share)			$ 65.75
Number of Shares Outstanding (in shares)	3,448,885	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 1.78	$ 2	$ 11.22

Note 3 - Stockholders' Equity_5

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Shares, options (in shares)	3,448,885	2,764,983
Shares, warrants (in shares)	3,319,265	1,951,257
Warrant One [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1	$ 1.07
Shares, warrants (in shares)	1,063,935	697,946
Weighted average remaining life, warrants (Year)	4 years 219 days	4 years 310 days
Warrant Two [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07	$ 2.25
Shares, warrants (in shares)	697,946	385,000
Weighted average remaining life, warrants (Year)	4 years 36 days	4 years 21 days
Warrant Three [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.155	$ 4.46
Shares, warrants (in shares)	1,071,776	756,999
Weighted average remaining life, warrants (Year)	5 years	3 years 335 days
Warrant Four [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25	$ 93.75
Shares, warrants (in shares)	385,000	2,255
Weighted average remaining life, warrants (Year)	3 years 116 days	69 days
Warrant Five [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 123.75	$ 123.75
Shares, warrants (in shares)	94,084	94,084
Weighted average remaining life, warrants (Year)	1 year 335 days	2 years 244 days
Warrant Six [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 150
Shares, warrants (in shares)	2,529	4,114
Weighted average remaining life, warrants (Year)	306 days	73 days
Warrant Seven [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 309.375	$ 225
Shares, warrants (in shares)	2,850	107
Weighted average remaining life, warrants (Year)	313 days	25 days
Warrant Eight [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 309.50	$ 243.75
Shares, warrants (in shares)	222	2,529
Weighted average remaining life, warrants (Year)	1 year 36 days	1 year 215 days
Warrant Nine [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 506.25	$ 281.25
Shares, warrants (in shares)	59	3,107
Weighted average remaining life, warrants (Year)	138 days	51 days
Warrant Ten [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.375	$ 309.375
Shares, warrants (in shares)	862	2,850
Weighted average remaining life, warrants (Year)	124 days	1 year 222 days
Warrant Eleven [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 309.50
Shares, warrants (in shares)		222
Weighted average remaining life, warrants (Year)		1 year 310 days
Warrant Twelve [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 337.50
Shares, warrants (in shares)		178
Weighted average remaining life, warrants (Year)		167 days
Warrant Thirteen [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 371.25
Shares, warrants (in shares)		944
Weighted average remaining life, warrants (Year)		149 days
Warrant Fourteen [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 506.25
Shares, warrants (in shares)		59
Weighted average remaining life, warrants (Year)		1 year 43 days
Warrant Fifteen [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 609.375
Shares, warrants (in shares)		862
Weighted average remaining life, warrants (Year)		1 year 32 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share)	$ 0.91	$ 1.01
Shares, options (in shares)	10,000	124,358
Weighted average remaining life, options (Year)	9 years 200 days	10 years
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share)	$ 0.965	$ 1.454
Shares, options (in shares)	3,000	17,200
Weighted average remaining life, options (Year)	9 years 229 days	9 years 273 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share)	$ 0.97	$ 1.47
Shares, options (in shares)	191,753	2,456,226
Weighted average remaining life, options (Year)	9 years 98 days	9 years 175 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share)	$ 1.01	$ 2.10
Shares, options (in shares)	149,110	14,286
Weighted average remaining life, options (Year)	9 years 138 days	9 years 91 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share)	$ 1.06	$ 2.25
Shares, options (in shares)	23,585	293
Weighted average remaining life, options (Year)	10 years	8 years 237 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share)	$ 1.10	$ 2.42
Shares, options (in shares)	86,958	24,768
Weighted average remaining life, options (Year)	9 years 259 days	8 years 138 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 1.13	$ 2.80
Shares, options (in shares)	195,931	57,145
Weighted average remaining life, options (Year)	9 years 292 days	9 years 3 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 1.15	$ 3.75
Shares, options (in shares)	21,740	44,000
Weighted average remaining life, options (Year)	9 years 306 days	8 years 182 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 1.16	$ 4.125
Shares, options (in shares)	66,451	3,636
Weighted average remaining life, options (Year)	9 years 306 days	8 years 273 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share)	$ 1.18	$ 4.1975
Shares, options (in shares)	30,000	7,147
Weighted average remaining life, options (Year)	9 years 313 days	8 years 262 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share)	$ 1.20	$ 4.25
Shares, options (in shares)	41,668	3,529
Weighted average remaining life, options (Year)	9 years 306 days	8 years 91 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share)	$ 1.21	$ 5.125
Shares, options (in shares)	30,000	3,902
Weighted average remaining life, options (Year)	9 years 313 days	8 years 251 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.35	$ 65.75
Shares, options (in shares)	111,112	190
Weighted average remaining life, options (Year)	9 years 164 days	7 years 146 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.454	$ 73.50
Shares, options (in shares)	17,200	1,157
Weighted average remaining life, options (Year)	9 years 3 days	8 years 3 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.47	$ 77.50
Shares, options (in shares)	2,347,308	2,323
Weighted average remaining life, options (Year)	8 years 266 days	7 years 182 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.10	$ 80.25
Shares, options (in shares)	14,286	187
Weighted average remaining life, options (Year)	8 years 182 days	7 years 273 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.25	$ 86.25
Shares, options (in shares)	293	232
Weighted average remaining life, options (Year)	7 years 328 days	7 years 91 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.42	$ 131.25
Shares, options (in shares)	20,640	81
Weighted average remaining life, options (Year)	7 years 306 days	4 years 251 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.80	$ 148.125
Shares, options (in shares)	57,145	928
Weighted average remaining life, options (Year)	8 years 94 days	5 years 76 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share)	$ 3.75	$ 150
Shares, options (in shares)	3,998	1,760
Weighted average remaining life, options (Year)	5 years 87 days	4 years 229 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share)	$ 4.125	$ 162.50
Shares, options (in shares)	3,636	123
Weighted average remaining life, options (Year)	8 years 3 days	7 years 3 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share)	$ 4.1975	$ 206.25
Shares, options (in shares)	7,147	121
Weighted average remaining life, options (Year)	7 years 354 days	6 years 273 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share)	$ 4.25	$ 248.4375
Shares, options (in shares)	3,529	121
Weighted average remaining life, options (Year)	7 years 182 days	5 years 197 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share)	$ 5.125	$ 262.50
Shares, options (in shares)	3,902	130
Weighted average remaining life, options (Year)	7 years 343 days	5 years 197 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share)	$ 65.75	$ 281.25
Shares, options (in shares)	190	529
Weighted average remaining life, options (Year)	7 years 21 days	5 years 14 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share)	$ 73.50	$ 318.75
Shares, options (in shares)	1,157	3
Weighted average remaining life, options (Year)	7 years 94 days	5 years 127 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 77.50	$ 346.875
Shares, options (in shares)	2,323	72
Weighted average remaining life, options (Year)	6 years 273 days	6 years 91 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 80.25	$ 431.25
Shares, options (in shares)	187	306
Weighted average remaining life, options (Year)	7 years 3 days	6 years 69 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 86.25	$ 506.25
Shares, options (in shares)	232	188
Weighted average remaining life, options (Year)	6 years 182 days	6 years
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share)	$ 131.25	$ 596.25
Shares, options (in shares)	81	42
Weighted average remaining life, options (Year)	3 years 343 days	5 years 273 days

Note 3 - Stockholders' Equity_6

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Shares, options (in shares)	3,448,885	2,764,983
Shares, warrants (in shares)	3,319,265	1,951,257
Minimum [Member]
Price, options (in dollars per share)	$ 0.91	$ 1.01
Warrant exercises, exercise price per share (in dollars per share)	0	0
Maximum [Member]
Price, options (in dollars per share)	596.25	596.25
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38	$ 609.38
Warrants 2013 [Member]
Shares, warrants (in shares)		10,705
Warrants 2013 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 93.75
Warrants 2013 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 371.25
Warrants 2014 [Member]
Shares, warrants (in shares)	6,455	6,455
Warrants 2014 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 243.75
Warrants 2014 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares)	94,151	94,152
Warrants 2015 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0	$ 0
Warrants 2015 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares)	252,333	756,999
Warrant exercises, exercise price per share (in dollars per share)	$ 1	$ 4.46
Warrants 2017 [Member]
Shares, warrants (in shares)	1,082,946	1,082,946
Warrants 2017 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07	$ 1.07
Warrants 2017 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25	$ 2.25
Stock Options 2011 [Member]
Shares, options (in shares)	173	173
Price, options (in dollars per share)	$ 281.25	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares)	1,841	1,841
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 131.25	$ 131.25
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 150	$ 150
Stock Options 2013 [Member]
Shares, options (in shares)	1,553	1,553
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 148.13	$ 148.13
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 596.25	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares)	836	835
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 162.50	$ 162.50
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 431.25	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares)	4,088	4,088
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 65.75	$ 65.75
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 86.25	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares)	100,292	144,423
Stock Options 2016 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 2.25	$ 2.25
Stock Options 2016 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 5.13	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares)	2,503,152	2,612,070
Stock Options 2017 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.01	$ 1.01
Stock Options 2017 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 2.10	$ 2.10

Note 4 - Notes Receivable (Deta

Note 4 - Notes Receivable (Details Textual) - USD ($)	Feb. 22, 2018	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Nov. 30, 2017	Oct. 31, 2017	Feb. 21, 2018	Jan. 11, 2018	Jul. 31, 2017
Advance to Helomics [Member]
Notes Receivable, Interest Rate, Stated Percentage						8.00%
Payments to Acquire Notes Receivable						$ 600,000	$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable			$ 60,000		$ 67,512.10
Lease to Purchase Equipment, Down Payment, Percentage					50.00%
Advances to De Lage Landen [Member] | Subsequent Event [Member]
Payments to Acquire Notes Receivable		$ 907,500
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage				8.00%						8.00%
Financing Receivable, Net, Total				$ 1,112,524	$ 1,070,000
Notes Receivable, Term				2 years
CytoBioscience [Member] | Promissory Notes Receivable [Member] | Subsequent Event [Member]
Notes Receivable, Interest Rate, Stated Percentage				8.00%
Financing Receivable, Net, Total				$ 1,112,524
Notes Receivable, Term				2 years
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total			$ 163,468
Share Exchange Agreement, Outstanding Receivables, Amount Converted				$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables				833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock				5.00%
Investment, Ownership Percent				25.00%
Helomics Holding Corp. [Member] | Subsequent Event [Member]
Financing Receivable, Net, Total	$ 167,512.50			$ 167,512.10				$ 667,512.50
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000			$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333			833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock				5.00%					5.00%
Investment, Ownership Percent	25.00%			25.00%

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,768,151	3,866,849	4,716,240	1,036,744
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			79,246
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			647,819

Note 5 - Loss Per Share - Share

Note 5 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)	3 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2018		Sep. 30, 2017		Sep. 30, 2018		Sep. 30, 2017		Dec. 31, 2017		Dec. 31, 2016
Net loss available in basic and diluted calculation	$ (2,506,869)		$ (992,095)		$ (6,640,301)		$ (4,877,542)		$ (7,746,593)		$ (6,526,014)
Unrealized gain (loss) from marketable securities							(1,501)				1,501
Comprehensive loss	$ (2,506,869)		$ (992,095)		$ (6,640,301)		$ (4,877,542)		$ (7,746,593)		$ (6,524,513)
Weighted average common shares outstanding-basic (in shares)	13,252,605		6,232,761		12,178,285		6,283,567		6,362,989		2,823,345
Effect of diluted stock options, warrants and preferred stock (1) (in shares)		[1]		[1]		[1]		[1]		[2]		[2]
Loss per common share - basic and diluted (in dollars per share)	$ (0.19)		$ (0.16)		$ (0.55)		$ (0.78)		$ (1.22)		$ (2.31)
[1]	The number of shares underlying options and warrants outstanding as of September 30, 2018 and September 30, 2017 are 6,768,151 and 3,866,849, respectively. The number of shares underlying the convertible debt as of September 30, 2018 is 5,047,700. The number of shares underlying the preferred stock as of September 30, 2018 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
[2]	The number of shares underlying options and warrants outstanding as of December 31, 2017 and December 31, 2016 are 4,716,240 and 1,036,744, respectively. The number of shares underlying the preferred stock as of December 31, 2017 is 79,246 for Series B Convertible and 647,819 for Series C Convertible. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes (Details

Note 6 - Income Taxes (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				34.00%
Income Tax Expense (Benefit), Total	$ 0	$ 0		$ 0
Valuation Allowance Percentage	100.00%			100.00%
Federal Income Tax Expense (Benefit), Continuing Operations, Total				$ 0
State and Local Income Tax Expense (Benefit), Continuing Operations, Total				0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total				34,500,000	$ 30,900,000
Operating Loss Carryforwards, Valuation Allowance, Total				7,400,000	10,700,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total				12,200,000	13,000,000
Operating Loss Carryforwards, Valuation Allowance, Total				$ 200,000	$ 200,000
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%

Note 6 - Income Taxes - Compone

Note 6 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Net Operating Loss	$ 7,393,100	$ 10,755,000
Other	215,843	189,000
Total Deferred Tax Asset	7,608,943	10,944,000
Less Valuation Allowance	7,608,943	10,944,000
Net Deferred Income Taxes	$ 0	$ 0

Note 7 - Rent Obligation (Detai

Note 7 - Rent Obligation (Details Textual)	12 Months Ended
	Dec. 31, 2017USD ($)ft²	Dec. 31, 2016USD ($)
Operating Leases, Rent Expense, Total | $	$ 66,122	$ 66,239
Corporate Office, Minnesota [Member]
Lessee Leasing Arrangements Operating Leases Terms of Contract Cancellation	3 years
Area of Real Estate Property	5,773
Corporate Office, Minnesota [Member] | Office Space [Member]
Area of Real Estate Property	2,945
Corporate Office, Minnesota [Member] | Manufacturing Facility [Member]
Area of Real Estate Property	2,828

Note 7 - Rent Obligation - Rent

Note 7 - Rent Obligation - Rent Obligation (Details)	Dec. 31, 2017USD ($)
2,018	$ 39,000
2,019	40,000
2,020	42,000
2,021	$ 3,000

Note 8 - Related Party Transa_4

Note 8 - Related Party Transactions (Details Textual) - GLG Pharma, LLC. [Member]	Sep. 20, 2016shares
Stock Expected to be Issued Upon Agreement, Shares	400,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche One	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Two	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Three	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Four	100,000

Note 9 - Retirement Savings P_2

Note 9 - Retirement Savings Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%	4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 29,952	$ 33,143
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 10 - Supplemental Cash F_2

Note 10 - Supplemental Cash Flow Data (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Interest Paid, Excluding Capitalized Interest, Operating Activities	$ 0	$ 3

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - USD ($)	Feb. 22, 2018	Feb. 21, 2018	Jan. 11, 2018	Feb. 22, 2017	Jan. 19, 2017	Oct. 04, 2016	Aug. 31, 2015	Mar. 31, 2018	Jan. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2018	Jul. 11, 2018	Jul. 10, 2018	Jan. 02, 2018	Dec. 28, 2017	Apr. 19, 2017	Dec. 31, 2016	Sep. 30, 2016
Stock Issued During Period, Shares, New Issues						400,000
Share Price																			$ 4.125
Proceeds from Issuance or Sale of Equity, Total							$ 13,800,000			$ 3,405,052
Common Stock, Par or Stated Value Per Share		$ 0.01				$ 0.01				$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01	$ 0.01	$ 0.01
Loans Receivable, Net, Total										$ 1,815,000		$ 1,815,000
Common Stock, Shares, Outstanding, Ending Balance										13,398,339	6,943,283	13,398,339						4,564,428
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues			1,100,000
Share Exchange Agreement, Shares Received			2,500,000
Share Exchange Agreement, Convertible Notes Receivable								$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock								5.00%
Share Exchange Agreement, Potential Interest								25.00%
Loans Receivable, Net, Total											$ 500,000
Share Exchange Agreement, Contingent Revenue, Minimum			$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent			20.00%
Financing Receivable, Net, Total										$ 163,468		$ 163,468
Share Exchange Agreement, Outstanding Receivables, Amount Converted								$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables								833,333
Investment, Ownership Percent								25.00%
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues									2,900,000
Share Price									$ 0.95
Proceeds from Issuance or Sale of Equity, Total									$ 2,755,000			2,755,000
The 2018 Public Offering [Member] | Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit									0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									1
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues		215,247
Proceeds from Issuance or Sale of Equity, Total				$ 358,312							$ 358,312	$ 358,312
Sale of Stock, Underwriter Option Term									45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase					175,000				290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase					35,000				87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase					$ 0.01				$ 0.001
Proceeds from Underwriter Shares Exercised, Net		$ 188,066
Stock Issued During Period, Underwriter Discount		$ 16,354
Underwriter Discount Percentage		8.00%
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share		$ 0.01													$ 0.01
Subsequent Event [Member] | Helomics Holding Corp. [Member]
Common Stock, Shares, Outstanding, Ending Balance	13,333,333	10,000,000
Subsequent Event [Member] | Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues			1,100,000
Share Exchange Agreement, Shares Received			2,500,000
Share Exchange Agreement, Convertible Notes Receivable			$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock			5.00%					5.00%
Share Exchange Agreement, Potential Interest			25.00%
Share Exchange Agreement, Contingent Revenue, Minimum			$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent			20.00%
Financing Receivable, Net, Total	$ 167,512.50	$ 667,512.50						$ 167,512.10
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000							$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333							833,333
Holding Interest, Preferred Stock		2,500,000
Holding Interest, Common Stock	3,333,333
Investment, Ownership Percent	25.00%							25.00%
Subsequent Event [Member] | The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues									2,900,000
Share Price									$ 0.95
Proceeds from Issuance or Sale of Equity, Total									$ 2,755,000
Subsequent Event [Member] | The 2018 Public Offering [Member] | Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit									0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									1
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 1
Subsequent Event [Member] | Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues		215,247
Share Price		$ 0.9497
Sale of Stock, Underwriter Option Term									45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase									290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase									87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase									$ 0.001
Proceeds from Underwriter Shares Exercised, Net		$ 188,066
Stock Issued During Period, Underwriter Discount		$ 16,354
Underwriter Discount Percentage		8.00%

Note 12 - Investment Securiti_3

Note 12 - Investment Securities and Other Comprehensive Income (Loss) - Cost and Fair Values of Investment Securities Available-for-sale (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Fair Value		$ 284,329
Mutual Fund [Member]
Cost		282,828
Gross Unrealized Gains		1,501
Gross Unrealized Losses
Fair Value		$ 284,329